Study Title: Clinical Study to investigate the effect of administratio n of selective 
serotonin reuptake inhibitors and an opioid on ventilation 
 
Document Title:  Clinical Study Protocol  – Study No.  SCR- 012 
 
Document Date: 21 July 2022 
 
Study ID: [REMOVED] 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 1 of 79 
  
 CLINICAL STUDY PROTOCOL 
 Clinical study to investigate the e ffect of administration of selective 
serotonin reuptake inhibitors and an opioid on ventilation 
 
PROTOCOL NO. SCR-012 
 
Sponsor: U.S. Food and Drug Administration 
White Oak Building #64, Room 2072 10903 New Hampshire Avenue Silver Spring, MD 20993  
Sponsor Study Lead: David Strauss, MD, PhD 
Director, Division of App lied Regulatory Science  
U.S. Food and Drug Administration Telephone: 301-796-6323 Email: david.strauss
@fda.hhs. gov 
  
Sponsor Medical 
Monitor: Keith Burkhart, MD 
U.S. Food and Drug Administration 
301-796-2226 Email: keith.burkhart
@fda.hhs. gov 
  
Project Manager: Jeffry Florian, PhD  
U.S. Food and Drug Administration  Telephone: 301-796-4847  Email: 
jeffry.florian @fda.hhs. gov 
  
 
Version of Protocol: 1.1 
 
Date of Protocol: 21 Jul y 2022 
 
CONFIDENTIAL 
The concepts and information contained in th is document or generated during the study 
are considered proprietary and may not be di sclosed in whole or in part without the 
expressed written consent of the U.S. Food and Drug Administration. 
 
 
U.S. FOOD AND DRUG ADMINISTRATION 
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory ScienceProtocol Number: SCR-012
(Version 1.1)
CONFIDENTIAL Page 2of 79SPONSOR SIGNATURE PAGE
This study will be conducted with the highest respect for the individual participants in 
accordance with the requirements of this clinical study protocol and also in accordance 
with the following:
xThe ethical principles that  have their origin in the Declaration of Helsinki;
xInternational Council for Ha rmonisation (ICH) harmonised tripartite guideline E6 
(R2): Good Clinical Practice; and
xAll applicable laws and regulations, incl uding without limitation, data privacy laws 
and compliance with appropriate regula tions, including human subject research 
requirements set forth by the In stitutional Review Board (IRB).
David Strauss, MD, PhD
Director, Division of Applied 
Regulatory Science 
U.S. Food and Drug AdministrationDate

U.S. FOOD AND DRUG ADMINISTRATION 
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory ScienceProtocol Number: SCR-012
(Version 1.1)
CONFIDENTIAL Page 3of 79INVESTIGATOR SIGNATURE PAGE
I confirm that I have read and that I understa nd this protocol, the investigator brochure, 
and other product information provided by th e sponsor. I agree to conduct this study in 
accordance with the requirements of this prot ocol and also protect the rights, safety, 
privacy, and well-being of study subject s in accordance with  the following:
xThe ethical principles that  have their origin in the Declaration of Helsinki;
xICH harmonised tripartite guideline E6 (R2): Good Clinical Practice;
xAll applicable laws and regulations, incl uding without limitation data privacy laws 
and regulations;
xHuman subject research require ments set forth by the IRB;
xRegulatory requirements for re porting of serious adverse events (SAEs) defined in 
Section 4.7.3.1 of this protocol; and
xTerms outlined in the Clinical Study Site Agreement.
I further authorize that my personal inform ation may be processe d and transferred in 
accordance with the uses contemplated in Section 6 of this protocol.
Jan Matousek, D.O.
Principal InvestigatorDate

U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 4 of 79 
  
 TABLE OF CONTENTS  
PROTOCOL SYNOPSIS ............................................................................................................. ............... 7  
1. INTRODUCTION ............................................................................................................... ................ 22  
2. STUDY OBJECTIVES ........................................................................................................... ............... 23  
2.1 PRIMARY OBJECTIVES  ..............................................................................................................................  23 
2.2 SECONDARY OBJECTIVES  ........................................................................................................................... 23  
2.3 EXPLORATORY OBJECTIVES  ........................................................................................................................ 24  
3. STUDY ENDPOINTS ............................................................................................................ .............. 24  
3.1 PRIMARY ENDPOINTS  .............................................................................................................................. . 24 
3.2 SECONDARY ENDPOINTS  ........................................................................................................................... 24  
3.3 EXPLORATORY ENDPOINTS  ........................................................................................................................ 24  
4. INVESTIGATIONAL PLAN ....................................................................................................... ........... 26  
4.1 STUDY DESIGN  .............................................................................................................................. ......... 26  
4.1.1 Risk/Benefit ............................................................................................................ .................... 27  
4.2 SELECTION OF STUDY POPULATION  ............................................................................................................. 30  
4.2.1 Inclusion Criteria ...................................................................................................... .................. 30  
4.2.2 Exclusion Criteria ...................................................................................................... .................. 31  
4.3 SCREENING FAILURES  .............................................................................................................................. . 33 
4.4 TERMINATION OF STUDY OR INVESTIGATIONAL SITE ....................................................................................... 34  
4.4.1 Criteria for Termination of the Study ................................................................................... ...... 34  
4.4.2 Criteria for Termination of the Investigational Site ....................................................................  34 
4.5 CRITERIA FOR SUBJECT WITHDRAWAL  ......................................................................................................... 34  
4.5.1 Handling of Withdrawals ................................................................................................. .......... 35  
4.5.2 Replacement of Subjects ................................................................................................. ........... 35  
4.6 STUDY VISITS .............................................................................................................................. ........... 36  
4.6.1 Recruitment ............................................................................................................. ................... 36  
4.6.2 Compensation ............................................................................................................ ................ 36  
4.6.3 Screening ............................................................................................................... ..................... 36  
4.6.4 Study Periods ........................................................................................................... ................... 37  
4.7 STUDY PROCEDURES  .............................................................................................................................. .. 40 
4.7.1 Pharmacokinetic Assessments ............................................................................................. ...... 40  
4.7.2 Pharmacodynamic Assessments ............................................................................................. ... 41  
4.7.3 Safety Assessments ...................................................................................................... .............. 44  
4.7.4 Demographics and Medical History ........................................................................................ ... 48  
4.8 STUDY TREATMENTS  .............................................................................................................................. .. 49 
4.8.1 Dose Strategy ........................................................................................................... .................. 49  
4.8.2 Treatments Administered ................................................................................................. .......... 49  
4.8.3 Dose Selection and Schedule ............................................................................................. ......... 50  
4.8.4 Method of Assigning Subjects to Treatment Sequence .............................................................. 51  
4.8.5 Identity of Study Drugs ................................................................................................. .............. 52  
4.8.6 Management of Clinical Supplies ......................................................................................... ...... 53  
4.8.7 Blinding ................................................................................................................ ...................... 54  
4.8.8 Treatment Compliance .................................................................................................... ........... 55  
4.8.9 Prior and Concomitant Me dications ....................................................................................... ... 55  
4.8.10 Subject Restrictions ................................................................................................... ............... 55  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 5 of 79 
  
 4.9 STATISTICAL METHODS  ............................................................................................................................ 5 6 
4.9.1 Sample Size ............................................................................................................. ................... 56  
4.9.2 Analysis Populations .................................................................................................... .............. 57  
4.9.3 General Statistical Co nsiderations ...................................................................................... ....... 57  
4.9.4 Subject Disposit ion ..................................................................................................... ................ 57  
4.9.5 Demographics and  Baseline Characteristics .............................................................................. 58 
4.9.6 Rebreathing Analyses .................................................................................................... ............. 58  
4.9.7 Pharmacokinetic Analysis ................................................................................................ .......... 59  
4.9.8 PK/PD Modeling .......................................................................................................... ............... 59  
4.9.9 Electrocardiogram Analyses .............................................................................................. ......... 60  
4.9.10 Additional Analyses .................................................................................................... .............. 60  
4.9.11 Safety Analyses ........................................................................................................ ................ 62  
4.9.12 Interim Analyses ....................................................................................................... ................ 63  
4.9.13 Missing Data ........................................................................................................... ................. 63  
4.10  DATA QUALITY ASSURANCE  .................................................................................................................... 63  
4.11  DATA SHARING  .............................................................................................................................. ....... 63  
5. ETHICAL CO NSIDERATIONS ..................................................................................................... ......... 64  
5.1 ETHICAL CONDUCT OF THE STUDY  .............................................................................................................. 64  
5.2 INSTITUTIONAL REVIEW BOARD (IRB) ......................................................................................................... 64  
6. ADMINISTRATIVE PROCEDURES .................................................................................................. ..... 64  
6.1 RESPONSIBILITIES OF THE INVESTIGATOR  ...................................................................................................... 64  
6.1.1 Form FDA 1572 ........................................................................................................... ................ 64  
6.1.2 Adherence to Protocol ................................................................................................... ............. 65  
6.1.3 Reporting Requirements .................................................................................................. .......... 65  
6.1.4 Source Documentation .................................................................................................... ........... 65  
6.1.5 Retention of Records .................................................................................................... .............. 65  
6.1.6 Financial Disclosure and  Obligations .................................................................................... ..... 65  
6.2 CONFIDENTIALITY AND DISCLOSURE OF DATA ............................................................................................... 66  
6.3 SUBJECT CONSENT  .............................................................................................................................. .... 66  
6.4 DATA COLLECTION  .............................................................................................................................. .... 67  
6.5 PUBLICATIONS  .............................................................................................................................. .......... 67  
7. STUDY MANAGEMENT ........................................................................................................... .......... 67  
7.1 MONITORING  .............................................................................................................................. ........... 67  
7.2 MANAGEMENT OF PROTOCOL AMENDMENTS AND DEVIATIONS  ....................................................................... 68  
7.2.1 Modification of the Protocol ............................................................................................ .......... 68  
7.2.2 Protocol Violations and Deviations ...................................................................................... ...... 68  
REFERENCE LIST ................................................................................................................ ................... 70  
8. APPENDICES ................................................................................................................. ................... 76  
APPENDIX A – SCHEDULE OF EVENTS  ................................................................................................................ 76  
APPENDIX B – LIST OF ABBREVIATIONS  ............................................................................................................. 77  
APPENDIX C – PROTOCOL REVISION HISTORY  ..................................................................................................... 79  
 
  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 6 of 79 
  
 LIST OF TABLES 
TABLE 4-1:  STUDY SCHEDULE  ..............................................................................................................................  26 
TABLE 4-2:  STUDY TREATMENT GROUPS  ............................................................................................................... 26  
TABLE 4-3:  CLINICAL LABORATORY TESTS & DIAGNOSTIC SCREENING TESTS ................................................................. 47  
 
 
 
 
 
 
  
  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 7 of 79 
  
 PROTOCOL SYNOPSIS 
Protocol Number: SCR-012 
Title: Clinical study to investigate the effect of selective serotonin reuptake 
inhibitors and an opioid on ventilation 
Investigators: Principal Investigator: Jan Matousek 
Study Physician: Jan Matousek 
Study Phase: 1 
Study Period: This is a 3-period, double-blind, randomized crossover study. The 
duration of each treatment period will  be 21 days in addition to a three-
week washout between periods. The duration of study participation will 
be 106 days (excluding the screening period). 
Study Site: Spaulding Clinical Research  Unit, West Bend, Wisconsin 
Background and 
Motivation: A well-known and potentially fatal a dverse reaction associated with 
opioid administration, partic ularly in the scenario of misuse, abuse, or 
when coadministered with certain other drugs is that people ‘stop 
breathing’. Research suggests this is caused by a reduced ventilatory 
response to increasing levels of  carbon dioxide. In August 2016, the 
U.S. Food and Drug Administration (FDA) included boxed warnings about increased potential for respir atory depression with co-use of 
benzodiazepines and opioids.
1 In response to this action, concerns were 
raised because patients may be prescribed other psychotropic drugs that may have similar adverse reactions  when combined with opioids. 
Subsequently, FDA performed a review of the literature and identified 
13 psychotropic drugs for evaluation in an in vivo animal study (using a 
rat model). The in vivo study identi fied 4 drugs that had significant 
effects when combined with oxyc odone on arterial carbon dioxide.
2 
Two drugs (quetiapine and paroxeti ne) were selected for further 
evaluation in a human clinical study evaluating drug effects on 
hypercapnic ventilation.  
To study the effects of opioids alone  or in combination with other 
psychotropic drugs on ventilation, FDA used a procedure referred to as 
Read rebreathing.3-4 With Read rebreathing, study participants rebreathe 
through a circuit with increased levels of O 2 and CO 2 . The artificially 
increased levels of CO 2 trigger the subjects to increase ventilation. This 
“hypercapnic ventilatory response”  can be decreased by opioids, 
benzodiazepines, and other drugs.5-19 
The previous study, which included 5-days of study drug dosing with 
oxycodone administered on da y 1 or 5 showed quetiapine co-
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 8 of 79 
  
 administered with oxycodone did not cause a significant decrease in 
hypercapnic ventilation co mpared to oxycodone alone.20 In contrast, 
paroxetine caused a decrease in hypercapnic ventilati on compared to 
oxycodone alone, and an additive effect  was seen when combined with 
oxycodone. This mechanism is due to a direct pharma codynamic effect, 
rather than a pharmacokinetic intera ction and most lik ely due to its 
serotonergic properties. Paroxetine is highly selective for inhibiting the 
serotonin transporter versus othe r monoamine transpor ters and other 
receptors in general.21-22 Although different type s of serotonergic 
receptors and neurons can have differential effects on breathing, paroxetine does not bind to serotonin receptors at clinically-relevant therapeutic exposures.
23-24 In addition, nonclinical and clinical studies 
have shown different SSRIs can have independent effects on ventilation, 
though SSRIs have not been shown to cause severe respiratory 
depression on their own.25-43 This supports the need for additional 
investigation on the effects of serotonergic drugs.  
The previous study evaluated effect s on ventilation over 5-days of 
dosing. SSRIs take approximately 3 w eeks to reach maximal therapeutic 
effect there, which correlates with  the time required for pre-synaptic 
inhibitory serotonergic receptors to desensitize.44-46 Drug-effects on 
ventilation should be evaluated for a similar time peri od to confirm if 
effects persist under steady state conditions 
As part of this proposed study with a longer dosing duration and 
different SSRIs, hypercapnic vent ilation will be assessed under 
hyperoxic and hypoxic gas levels usi ng a modified Read rebreathing 
approach referred to as Duffin rebr eathing. These modifications allow 
for critical physiological measuremen ts and thresholds to be captured 
that can then be used to model the effects of drugs when there are dynamic changes in PO
2 and PCO 2, such as during a real-world opioid 
overdose.47-52  
Objectives and Endpoints: The objectives of this study are: 
Primary Objectives 
Primary objectives include the following: 
x To study ventilatory effect s of SSRIs (paroxetine or 
escitalopram) combined w ith oxycodone compared to 
oxycodone alone after 21 days of SSRI dosing  
x To study ventilatory effect s of SSRIs (paroxetine or 
escitalopram) compared to placebo  after 20 days of SSRI dosing  
 
Secondary Objectives Secondar
y objectives include the followin g: 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 9 of 79 
  
 x To compare ventilatory effect s of SSRIs (paroxetine or 
escitalopram) combined w ith oxycodone compared to 
oxycodone alone after 6 and 12 days of SSRI dosing  
x To compare ventilatory effect s of SSRIs (paroxetine or 
escitalopram) compared to placebo after 5 and 11 days of SSRI dosing  
 
Exploratory Objectives 
x To study whether paroxetine or escitalopram affects the 
pharmacokinetics of oxycodone  
x To evaluate differences in hypercapnic ventilatory response 
under hyperoxic or hypoxic rebreathing  
x To study whether there is a dire ct pharmacodynamic  interaction 
between paroxetine or escitalopram and oxycodone 
x To summarize additional pharm acokinetic parameters and 
pharmacodynamic measurements collected during the study 
The endpoints for this study are: 
Primary Endpoint  
x Minute ventilation at the 55mm Hg end tidal CO
2 point (VE55) 
under hyperoxic conditions on day 21  
x VE55 under hyperoxic conditions on day 20 
 
Secondary Endpoints Secondary endpoints include the following: 
x VE55 under hyperoxic conditions on days 6 and 12 
x VE55 under hyperoxic conditions on days 5 and 11 
 Exploratory Endpoints  
x The maximum observed pl asma concentration (C
max) and area 
under the plasma concentration time curve (AUC) of oxycodone 
and oxymorphone on days 6, 12, and 21  
x Baseline minute ventilation, ventila tory recruitment threshold, 
slope of the minute ventilation / end-tidal partial pressure of 
carbon dioxide (end-tidal PCO 2) regression line, and 
extrapolated ventilatory recruitment threshold collected during hyperoxic and hypoxic rebreathing 
x The PK/PD relationship for st udy drugs when administered 
alone or in combination with oxycodone 
x Additional pharmacokinetic  and pharmacodynamic (e.g., 
ventilation, pupillometry, ECG) e ndpoints as specified in the 
protocol 
 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 10 of 79 
  
 Study Design: This study will be a randomized, do uble blind, three period crossover 
study with approximately 25 healthy volunteer participants. This study 
will include three 21-day treatment  periods with a 3-week washout 
between each period. Each subject will be randomized to 1 of 6 
treatment sequences (i.e., ABC, ACB, BAC, BCA, CAB, CBA). FDA 
will prepare the randomization schedule. 
Study Schedule: 
 
Study Treatments:  
 
 
Subjects will report to the study site for screening from Days -28 to -2. 
During the screening visit, the inclusion and exclusion criteria will be reviewed to ensure the subject is appropriate for the study. The informed 
consent form will be reviewed with  the subject by a member of the 
study team and the subject will be enc ouraged to ask questions to ensure 
he or she has a good understanding of th e study. If the subject is eligible 
and agrees to participate, the subject will be asked to sign the informed consent form before any study-sp ecific procedure is performed, 
including randomization. 
After the consent process is comp lete, demographic data, medical 
history, and concomitant medicatio ns will be recorded. A physical 
examination will be performed by a study team member. Clinical 
laboratory tests (hemat ology, seum chemistry, and urinalysis) will be 
performed. Female subjects must have a negative pregnancy test result. 
Screening tests will be performed wi thin 28 days of and no later than 2 
days before Day 1. 
At check-in for the first period (Day -1), eligibility criteria will be 
reviewed, any changes in medica l history (including concomitant 
medications) will be documented. At check-in for all periods, vital si
gn Day -1  Days 1-21 Days 22-42 Days 42-63 Days 64-84  Days 85-105 Day 
106 
Check-in  Period 1 Washout Period 2  Washout  Period 3  Check-
out 
Treatment Day 
1-5 6 7-11 12 13-20 21 
A Placebo QD Placebo + 
10 mg 
oxycodone Placebo QD Placebo +  
10 mg 
oxycodone Placebo QD Placebo  + 
10 mg 
oxycodone 
B 40 mg 
paroxetine QD 40 mg 
paroxetine + 
10 mg 
oxycodone 60 mg 
paroxetine QD 60 mg 
paroxetine + 
10 mg 
oxycodone 60 mg 
paroxetine QD 60 mg 
paroxetine + 
10 mg 
oxycodone 
C 20 mg 
escitalopram 
QD 20 mg 
escitalopram +  
10 mg oxycodone 30 mg 
escitalopram 
QD 30 mg 
escitalopram +  
10 mg oxycodone 30 mg 
escitalopram 
QD 30 mg 
escitalopram + 
10 mg 
oxycodone 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 11 of 79 
  
 measurements, and a 12-lead electrocardiogram (ECG) will be 
performed. In addition, clinical  laboratory, drug, alcohol, two 
rebreathing assessments (one hyperoxic and one hypoxic), and a 
COVID-19 rapid antigen. An intrave nous (IV) catheter may be inserted 
into the subject’s forearm region for blood collection (if needed).  
Participants will enter the clinic on a staggered basis in cohorts of 
approximately five so that no more  than five subjects are undergoing 
rebreathing on any given day. Subjects  will be staggered to allow for 
direct safety overview by medical staff during Duffin’s rebreathing.  
Participants will receive either plac ebo, paroxetine, or escitalopram on 
days 1-21 for each period. Oxycodone  will be administered on days 6, 
12, and 21 of each period. Dosing of the study drugs will occur at time 0 on each day. Oxycodone dosing will be at 3 h so that maximum 
concentration occurs for all drugs is at approximately the same time.   
Participants will be confined to th e study clinic from day -1 until the 
first day of each washout period. Th ere will be a three-week washout 
between each period. Subjects will be discharged from the study after 
completion of all study procedures. If a subject discontinues from the 
study prematurely, all procedures sche duled for the end of the study will 
be performed. Meal timing and compone nts, activity levels, and general 
conditions in the study clinic will be as similar as possible on the 
treatment days. 
Upon return to clinic, on Days 42 & 84, eligibility criter ia to continue 
study participation will be reviewed (s ee Schedule of Events for criteria 
listed on Days 42 & 84), any change s in medical history (including 
concomitant medications) will be documented. 
Subject Population: Approximately 25 healthy participants are planned for enrollment. 
Every effort will be made to main tain an approximate 50:50 male-to-
female sex distribution.  
Study and Reference Drugs, Dosage, and Route of Administration: For all drugs, standard drug doses or  doses used in prior studies in 
healthy participants will be used in this study. Multiple doses of the 
assigned study drug will be adminis tered to each subject during the 
treatment period. Oxycodone, paroxe tine, escitalopram, ondansetron, 
and placebo will be administered oral ly. Subjects will complete each of 
the three treatments (A, B, and C) and will receive the following drugs alone or in combination:  
x Oxycodone 10 mg QD (2 x 5 mg tablets) on days 6, 12, and 21 
in each treatment (A-C)  
x Paroxetine 40 mg QD (2 x 20 mg  tablet) on days 1-6 and 60 mg 
QD (3 x 20 m
g tablets) on da ys 7-21 in treatment B 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 12 of 79 
  
 x Escitalopram 20 mg QD (2 x 10 mg tablet) on days 1-6 and 30 
mg QD (3 x 10 mg tablets) on days 7-21 in treatment C 
x Matching oral placebo for pa roxetine and es citalopram 
x Participants will also receive ondansetron 4 mg orally 30 min 
before ox ycodone administration 
Inclusion Criteria: Subjects who meet all the following incl usion criteria will be eligible to 
participate in the study:  
1. Subject signs an IRB approved written informed consent and 
privacy language as pe r national regulations (e.g., Health Insurance 
Portability and Accountability Act authorization) before any study 
related procedures are performed.  
2. Subject is a healthy, non-smoki ng man or woman, 18 to 50 years 
of age, inclusive, who has a body mass index of 18.5 to 33.0 
kg/m2, inclusive, at Screening. 
3. Subject has normal medical histor y findings, clinical laboratory 
results, vital sign measuremen ts, pulse oximetry, 12-lead ECG 
results, and physical examination findings at screening or, if 
abnormal, the abnormality is not c onsidered clinically significant 
(as determined and documented by th e investigator or designee). 
4. Subject must have a negative test  result for alcohol and drugs of 
abuse at screening and check-in days.  
5. Subject must test negative for se vere acute respiratory syndrome 
corona virus 2 (SARS-CoV-2) by a rapid antigen te st at check-in 
for all study periods. If a subject’s test comes back as invalid, the 
test can be repeated. 
6. Female subjects must be of non-c hildbearing poten tial (confirmed 
with follicle-stimulating hormone le vels > 40 mIU/mL)  or, if they 
are of childbearing potential, they must: 1) have been strictly 
abstinent for 1 month before check-i n (Day -1) and agree to remain 
strictly abstinent for the durati on of the study and for at least 
1month after the last application of  study drug; OR 2)  be practicing 
2 highly effective methods of birt h control (as de termined by the 
investigator or designe e; one of the methods  must be a barrier 
technique) from at least 1 month before check-in (Day -1) until at least 1 month after th e end of the study.  
7. Male subjects must agree to prac tice 2 highly eff ective methods of 
birth control (as determined by th e investigator or designee) from 
at least 1 month before check-in (Day -1) until at least 1 month 
after the last dose of study drug. 
8. Subject is highly likely (as dete rmined by the investigator) to 
comply with the protocol defined procedures and to complete the 
stud
y. 
Exclusion Criteria: Subjects who meet any of the followi ng exclusion criteria will not be 
eligible to participate in the stud y: 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 13 of 79 
  
 1. Subject has used any prescr iption or nonprescription drugs 
(including aspirin or NSAIDs and excluding oral contraceptives and 
acetaminophen) within 14 days or 5 half-lives (whichever is longer) 
or complementary and a lternative medicines within 28 days before 
the first dose of study drug. This includes prescription or nonprescription ophthalmic drugs. 
2. Subject is currently pa rticipating in another clinical study of an 
investigational drug or has been treated with any investigational 
drug within 30 days or 5 half-liv es (whichever is longer) of the 
compound. 
3. Subject has used nico tine-containing products  (e.g., cigarettes, 
cigars, chewing tobacco, snuff,  electronic cigarettes) within 
6 weeks of Screening. Subjects must refrain from using these 
throughout the study. 
4. Subject has consumed alcohol, xa nthine containing products (e.g., 
tea, coffee, cola), caffeine, grap efruit, or grapefruit juice within 
24 h of check-in. Subjects must  refrain from ingesting these 
throughout the study.  
5. Subject has a history or evidence of a clinically significant disorder, 
condition, or disease (e.g., cancer, human immunodeficiency virus 
[HIV], hepatic or renal impairme nt) that, in the opinion of the 
investigator would pose a risk to su bject safety or interfere with the 
study evaluation, procedures, or co mpletion. This includes subjects 
with any underlying medical condi tions that put subjects at 
increased risk of severe i llness from COVID-19 based on the 
Centers for Disease Control a nd Prevention (CDC) guidelines. 
6. Subject has any signs or symptoms at screening or check-in of any 
study period that are consistent  with COVID-19. Per current CDC 
recommendations this includes su bjects with the symptoms cough 
or shortness of breath or  difficulty breathing, or at least two of the 
following symptoms: fever, chills, repeated shaking with chills, 
muscle pain, headache, sore throat, or new loss of taste/smell. In addition, the subject has any othe r findings suggestive of COVID-
19 risk in the opinion of the investigator. 
7. Subject has known or suspected alle rgies or sensitivities to any 
study drugs. 
8. Subject has clinical laboratory test resu lts (hematology, serum 
chemistry and urinalysis) at Screen ing or period check-In that are 
outside the reference ranges provi ded by the clinical laboratory and 
considered clinically significan t by the investigator. Clinical 
laboratory results may be repeated  once, as needed, for confirming 
results at Screening a nd period check-in.   
9. Subject has a positive test resu lt at Screening for HIV 1 or 2 
antibody, hepatitis C virus antibodies, or hepatitis B surface anti
gen. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 14 of 79 
  
 10. Subject is unable or unwilling to  undergo multiple venipunctures 
for blood sample collection because of poor tolerability or poor 
venous access. 
11. Female subject is currently pregna nt or lactating or was within 3 
months of study enrollment. 
12. Subject has a history of  opioid or psychotropic drugs within 60 days 
of the start of the study. 
13. Subject has a history of asthma th at has required medication within 
the last five years. 
14. Subject has non-reactive or mishapp en pupil(s) or damaged orbit 
structure or surrounding soft tissue is edematous or has an open 
lesion. 
15. Subject has a Mallampati score of >2. 
16. Subject’s Duffin rebreathing data is  of poor quality or subject does 
not agree to remain cl ean-shaven for all days when the Duffin 
rebreathing procedure is performed. 
17. Subject has a history of  sleep disorders, Panic disorders, Panic 
Attacks, Generalized Anxiety Di sorder, or any associated DSM 
diagnosis or condition. 
18. Subject has a history of or curr ently has hypoventilation syndrome 
or sleep apnea and is on non-invasive ventilation. 
19. Subject has a history of unexplai ned syncope, structural heart 
disease, long QT syndrome, hear t failure, myocardial infarction, 
angina, unexplained cardiac a rrhythmia, TdP, ventricular 
tachycardia, or placement of  a pacemaker or implantable 
defibrillator. Subjects will be also excluded if there is a family 
history of long QT syndrome (gen etically proven or suggested by 
sudden death of a close relative to cardiac causes at a young age) or 
Brugada syndrome. 
20. Subject has a history of suicidal  ideation or previous suicide 
attempts. 
21. Subject has a safety 12- lead ECG result at screening or check-in at 
any study period with eviden ce of any of the following 
abnormalities:  
x QTc using Fridericia correction (QTcF)>430 msec 
x  PR interval>220 msec or <120msec 
x QRS duration>110 msec 
x Second- or third-degree atrioventricular block 
x Complete left or righ t bundle branch block or incomplete right 
bundle branch block 
x Heart rate <50 or >90 beats per minute 
x Pathological Q-waves (defin ed as Q-wave>40 msec) 
x Ventricular pre-excitation  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 15 of 79 
  
 22. Subject has a skin condition lik ely to compromise ECG electrode 
placement. 
23. Any individual with breast implants.  
 
Sample Collection The following samples should be collected and processed as follows. 
Number of samples collected through out the study can be found in the 
Schedule of Events (see Appendix): 
The PK blood samples (6 mL each) will be collected into tubes 
containing K2EDTA, inverted several times to mix the blood with the 
anticoagulant, and placed in an ice bath. Within 30 minutes of 
collection, the samples will be ce ntrifuged for 10 minutes, at 3000 
relative centrifugal force (RCF), at 4°C, by a study team member. 
The plasma will be separated using a disposable plastic pipette and 
equally aliquoted into duplicate cr yotube vials labeled as Aliquot A 
(primary) and Aliquot B (backup) . The plasma samples will be 
appropriately labeled and stored fro zen at -70°C or below within 30 
minutes after aliquoting until shipment. Temperature monitoring logs should be maintained and accessible fo r review by the study monitor.  
The Aliquot A samples (primary) will be  shipped first, on dry ice, to the 
bioanalytical laboratory at FDA fo r processing when requested by the 
sponsor. The Aliquot B samples (bac kup) will be held for a second 
shipment after completion of all Aliquot A sample shipment(s) and the timing of the Aliquot B shipment will be communicated by the sponsor. 
None of the PK blood samples will be st ored at the clinical facility for 
future use. 
Pharmacokinetic Assessments: Pharmacokinetic blood samples will be  collected on the following days 
at the approximate time s for each study period: 
x Day 5, 6, 11, 12, 20, and 21: 0 (pre-dose), 3, 4, 5, 8 hr (and 24 hr 
for Day 6, 12, and 21) 
x Day 2 and 16: 0 (pre-dose), 2, 3, 4, 5, 6, 8, 12, 24 hr 
Blood samples will be collected by direct venipuncture or by inserting 
an IV catheter. There wi ll be a total of 51 PK samples per participant for 
each study period. 
For each participant, the following PK  parameters will be determined 
for oxycodone and oxymorphone (days 6, 12, and 21) and paroxetine escitalopram, and escitalopram metabolites (days 2, 5, 6, 11, 12, 16, 20, 
and 21): 
x Maximum observed plasma concentration (C
max) 
x Area under the plasma concen tration time curve (AUC) 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 16 of 79 
  
 x Time at which C max occurs (T max) 
x Elimination rate constant (K el) 
x Terminal half-life (t 1/2) 
x Accumulation ratio (for esci talopram and paroxetine) 
 
Pharmacodynamic Assessments:  
 Rebreathing assessments following Du ffin’s rebreathing procedure (see 
separate Standard Operating Proced ure [SOP]) will be performed on the 
following study days and time of each study period: 
x Day -1: one hyperoxic and one hypoxic assessment 
x Day 5, 6, 11, 12, 20, and 21: hyperoxic assessments at 0 (pre-
dose), 4 and 5 hours; one hypoxi c assessment at 5 hours 
(following the hyperoxic assessment) 
During Duffin’s rebreathing procedure, subjects will be placed in an 
upright position (90
o angle) on a bed and connected to the respiration 
measurement set up. Subjects will we ar a facemask and breathe from a 
pre-filled rebreathing ba g containing approximately 4 L of either a 
hyperoxic-hypercapnic (24% O 2, 6% CO 2, N2 balanced) or hypoxic-
hypercapnic (6% O 2, 6% CO 2, N2 balanced) gas mixture. During this 
study, subjects will be asked to brea th room air for 5 minutes (relaxation 
stage) and then to hyperv entilate (primarily th rough deep breathing) 
room air voluntarily for 5 minutes (hyperventilati on stage). Thereafter, 
subjects will be switched to the rebr eathing bag and perform rebreathing 
assessments at one of the 2 different isoxic end tidal PO 2, i.e., 150 
mmHg and 50 mmHg. The isoxia at 150 mmHg or 50 mmHg end-tidal PO
2 will be maintained by providing a computer-controlled flow of 
100% O 2 to the rebreathing bag.  
Pupillary assessments (see separate SOP) will be performed before and 
after each rebreathing procedure (ex cept not in between the hyperoxic 
and hypoxic paired assessment) while the ambient light is kept at a 
consistent level. The rubber cup of  the pupillometer wi ll be placed on 
the right eye and repeated on the same  eye approximately 1 minute later. 
ECG assessments will be performed  on the following study days and 
time of each study period: 
x Day 1: 0 (pre-dose) hr 
x Day 2 and 16: 0 (pre-dose), 2, 3, 4, 5, 6, 8, 12, 24 hr 
Ten second 12-lead ECG tracings with  the most stable heart rate and 
highest signal-to-noise ratio  will be extracted in at least 3 replicates at 
ECG extraction time points dur ing each treat ment period. 
During all ECG extraction periods, s ubjects will be placed in a supine 
position. Three ECG extractions will be performed for a baseline 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 17 of 79 
  
 measurement before the first oral  dose on day 1 of each treatment 
period. The other ECG extractions/p eriod time matched to the PK 
samples will be obtained before the PK  sample collecti on time. Subjects 
will be isolated (not able to see each  other) in a quiet environment that is 
free from external stimuli. 
Different ventilation, cardiovasc ular, pupillary, sedation, and ECG 
measures that will be summarized include, but are not limited to, the 
following: 
Ventilation and Cardiova scular Assessments:  
x During rebreathing stage 
o VE55  (minute ventilation at th e 55mm Hg end tidal CO 2 
point) 
o Baseline minute ventilation  when end tidal PCO 2 is less 
than the ventilatory recruitment threshold (represents non-chemoreflex drives to breathe) 
o Ventilatory recruitment threshold  (end tidal PCO
2 above 
which minute ventilation starts to increase linearly with further increases in end tidal PCO
2) 
o Slope of the minute venti lation / end-tidal partial 
pressure of carbon dioxide (end-tidal PCO 2) regression 
line that reflects the increase in minute ventilation 
relative to the increase in end tidal PCO 2 (represents 
chemoreflex sensitivity)  
o Extrapolated ventilation recruitment threshold  
(intersection with X axis) 
x During relaxation stage 
o Minute ventilation, tidal volum e, respiratory rate, end-
tidal PCO 2, end-tidal PO 2, oxygen saturation, and heart 
rate during the relaxation stage 
o Number of apneic events lasting > 10 s during the 
relaxation stage 
 
Pupillary Assessments  
x Maximum pupil diameter before constriction  
x Minimum diameter at peak constriction  
x Percent change between  min/max diameter  
x Latency of constriction   
x Average constriction velocity  
x Maximum constriction velocity  
x Dilation velocity after peak constriction  
x Time to reach 75% recovery  of maximum diameter  
 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 18 of 79 
  
 Sedation scores   
x Ramsey Sedation Scale   
x Visual Analogue Scale   
 
ECG Assessments  
x Change from baseline in QTc,  PR, QRS, JT peakC, TpeakTend and 
heart rate. 
 In addition, PK/PD relationships will  be evaluated between study drugs 
and a subset of pharmacodynamic endpoints (ventila tion, pupillary, 
ECG).  
Safety Assessments: 
 Safety will be evaluated in terms of  adverse events (AEs), clinical 
laboratory results (hematology, serum ch emistry, and urinalysis), vital 
sign measurements (blood pressure, hear t rate, respiratory rate, and oral 
body temperature), safety 12-lead ECG, and physical examination 
findings. 
Sample Size and Threshold Determination: Approximately 25 healthy participants are planned for enrollment. A 
previous study (20 partic ipants) with paroxetine showed a decrease of 
10.2 L/min in VE55 for paroxetine (40 mg) combined with oxycodone (10 mg) compared to oxycodone alone  after 5 days of dosing with 
paroxetine. Similarly, there was a 9.3 L/min decrease in VE55 for paroxetine compared to placebo after 4 days of dosing with paroxetine. 
The standard deviation in assess ments was approximately 6.5 L/min. 
Assuming a similar effect size with paroxetine and escitalopram at day 
20 and 21, the planned number of participants allows for a 40% drop out rate while maintaining at least 90% po wer for separate one-sided tests at 
a 0.025 significance level with th e multiple primary endpoints. 
 
Statistical Methods: All data will be presented in data  listings. Data from subjects excluded 
from an analysis population will be pres ented in the data listings but not 
included in the calculation of su mmary statistics. The number of 
subjects who enroll in the study and the number and percentage of 
subjects who complete each asse ssment will be presented. The 
frequency and percentage of subjects  who withdraw or discontinue from 
the study and the reason for withdr awal or discontinuation will be 
summarized. Demographic and baseline characteristics will be summarized overall and by treatment for all subjects. 
Descriptive statistics will be us ed to summarize demographic and 
baseline subject characteristics. For continuous variables, the mean, 
median, standard deviation (SD), minimum, and maximum values will 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 19 of 79 
  
 be reported. For categorical (no minal) variables, the number and 
percentage of subjects (or observations) will be reported. 
The rebreathing analysis populati on will include all subjects who 
completed at least one rebreathing assessment on any day or at any 
timepoint. Specific information on an alysis populations for different 
pharmacodynamic measures wi ll be described in the Statistical Analysis 
Plan (SAP). 
 
Primary and Secondary Ventilation Analyses 
Multiple primary analyses are planned for each drug. The first primary 
analysis will be VE55 on day 21 at 5 h (hyperoxic) between oxycodone 
with paroxetine or escitalopram  compared to oxycodone alone. The 
second primary analysis will be VE 55 on day 20 at 5 h (hyperoxic) 
between paroxetine or escitalopram compared to placebo. Since Day 20 
and 21 are considered multiple pr imary endpoints, comparisons will 
have an adjustment for multiplicity using a Bonferroni correction (each day will be tested at a 0.025 significa nce level). No adjustments will be 
made for separate testing of par oxetine or escita lopram since the 
treatments are considered separate interventions in the study.  
A linear mixed effects model will be  developed using all study data 
from hyperoxic assessments . Fixed effects will include treatment, 
period, sequence, and baseline VE55 (i.e., VE55 obtained at 0 h on Day 
-1 of each treatment period).  S ubject will be included as a random 
effect on the intercept.  If a subj ect’s baseline VE55 for a treatment 
period is not available, then the ba seline value for that period will be 
calculated based on the median of al l other baseline values for that 
subject from other study periods. If a subject does not have any 
completed baseline VE55 data, the s ubject will be assigned a baseline 
VE55 equal to the median of the population.  
To demonstrate an effect when oxyc odone is combined with paroxetine 
(or escitalopram) compared to oxycodone the upper bound of the one-
sided 97.5% CI of the least-squa re mean VE55 difference between 
treatments must not overlap 0 L/min.  Similarly, to demonstrate an 
effect of paroxetine (or escital opram) compared to placebo the upper 
bound of the one-sided 97.5% CI of the least-square mean VE55 difference between treatments mu st not overlap 0 L/min. Each 
comparison will be performed separately (i.e.,‘trt’ as ‘paroxetine’ or ‘escitalopram’).:  
x H0: VE55oxy+trt - VE55oxy  0 L/min 
x HA: VE55ox
y+trt - VE55ox y < 0 L/min 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 20 of 79 
  
 For secondary endpoints, effects of paroxetine or escitalopram with 
oxycodone compared to oxycodone alone will also be performed using 
the same comparisons on day 6 and day 12. 
As additional secondary endpoints, effe cts of paroxetine or escitalopram 
alone compared to placebo will be determined on day 5 and 11 using the same model. Additional details on testing of ventilation secondary 
endpoints are discussed in the SAP. 
Pharmacokinetics : Concentrations will be determined at approximately 
specified timepoints. O xycodone and oxymorphone C
max and AUC will 
be summarized on days 6, 12, and 21 using descriptive statistics. 
Differences in oxycodone or oxymorphone  alone compared to exposures 
when coadministered with paroxetine  or escitalopram will be compared. 
Cmax and AUC will be log-transformed and the values between study 
arms will be compared using a li near mixed effects model with 
treatment as a categorical variable an d participant as a random effect.  
Paroxetine and escitalopram C max and AUC will be summarized on days 
2, 5, 6, 11, 12, 16, 20 and 21 using descriptive st atistics.  
The PK parameters will be analyz ed using noncompartmental methods 
based on actual sampling times. All parameters will be calculated using SAS or R software. Mean  and individual concentration time profiles 
will be presented in graphs. 
Additional PK parameter analyses in cluding but not limited to measures 
listed under Pharmacokinetic Assessments will be included in the SAP. 
Additional Pharmacodynamics on Ventilatory Assessment Days : 
Mean and standard deviations for baseline minute ventilation, 
ventilatory recruitment th reshold, slope of the PCO
2-ventilatory 
response curve, and the extrapolated  ventilatory recr uitment threshold 
will be calculated for each subject at each rebreathing assessment using data from the rebreathin g stage. Mean and standard deviation for minute 
ventilation, tidal volume, resp iratory rate, end-tidal PCO
2, end-tidal 
PO 2, oxygen saturation, and heart rate will be calculated using data from 
the relaxation stage. Number of apneic events lasting > 10s will be counted for each subject, day, and rebreathing assessment during the 
relaxation stage. Full details will be  described in a separate SAP. 
Additional pupillary assessments (e.g., ventilatio n, respiratory rate, heart 
rate, maximum pupil diameter before constriction) as specified in the protocol will be reported with standard descriptive statistics. 
ECG Assessments  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 21 of 79 
  
 Intensive ECG assessments will be  performed on Days 2 and Day 16. 
The QT interval will be corrected for heart rate using Fridericia’s formula (QTc=QT/RR
1/3). The J-T peak interval will be corrected for heart 
rate using the formula (J-T peakC = J-T peak/RR0.58). Baseline will be the 
mean of the 3 predose EC G extractions of Day 1. 
Exposure-response analyses will be  performed for the change from 
baseline in QTc (and other ECG measurements; see ECG Analysis 
Plan), where the mean of the 3 predose ECG readings on Day 1 will be 
used as the Baseline. The concentration of the drug will be used as a covariate. Exposure-response analysis  will be done following most 
recent best practices in concentra tion-QTc modeling. Additional details 
will be specified in the ECG Analysis Plan.  
Safety 
The safety population will include al l subjects who receive at least 1 
dose of the study drug. All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of AEs, 
organized by system organ class a nd preferred term, will be summarized 
with a focus on treatment-emergent AEs. Vital sign measurements will 
be summarized using descriptive stat istics by time point. All values will 
be evaluated for clinically notable results. Data for additional safety 
parameters (e.g., physical examin ation findings) will be listed. 
Date of Protocol: 21 July 2022 
 
  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 22 of 79 
  
 1. INTRODUCTION 
A well-known and potentially fatal adve rse reaction associated with opioid 
administration, particularly in the scenario of misuse, abus e, or when co-administered 
with certain other drugs is that people ‘stop breathing’. Research sugge sts this is caused 
by a reduced respiratory response to counter act increasing levels of systemic carbon 
dioxide (CO 2). In August 2016, the U.S. Food and Drug Administration (FDA) included 
boxed warnings about increased potential for respiratory depression with co-use of 
benzodiazepines and opioids.1  In response to this action, concerns were raised because 
patients may be prescribed other psychotr opic drugs that may have similar adverse 
reactions when combined with opioids.  
Subsequently, FDA performed a review of th e literature and identified 13 psychotropic 
drugs for evaluation in an in vivo animal study (using a rat model) . The in vivo study 
identified 4 drugs that had significant effect s when combined with oxycodone on arterial 
carbon dioxide.2 Two drugs (quetiapine and paroxe tine) were selected for further 
evaluation in a human clinical study eval uating drug effects on hype rcapnic ventilation.  
To study the effects of opioids alone or in combination with other psychotropic drugs on 
ventilation, FDA used a procedure re ferred to as Read rebreathing.3-4 With Read 
rebreathing, study participants rebreathe th rough a circuit with increased level of O 2 and 
CO 2 (93% O 2 and 7% CO 2). The artificially increased levels of CO 2 trigger the subjects to 
increase ventilation. This “hypercapnic ventilatory response” can be decreased by 
opioids, benzodiazepines, and other drugs.5-19     
The previous study, which included 5-da ys of study drug dosing with oxycodone 
administered on day 1 or 5 showed quetiapine  co-administered with oxycodone did not 
cause a significant decrease in hypercapnic ventilation compared to oxycodone alone.20  
In contrast, paroxetine caused a decreas e in hypercapnic vent ilation compared to 
oxycodone alone, and an additive  effect was seen when combined with oxycodone. This 
mechanism is due to a dir ect pharmacodynamic effect, ra ther than a pharmacokinetic 
interaction and most likely due to its serotonergic prope rties. Paroxetine is highly 
selective for inhibiting the serotonin transpor ter versus other monoami ne transporters and 
other receptors in general.21-22 Although different types of serotonergic receptors and 
neurons can have differential effects on breathing, paroxetine  does not bind to serotonin 
receptors at clinically-relevant exposures.23-24 In addition, nonclinical  and clinical studies 
have shown different selec tive serotonin reup take inhibitors (SSRIs) can have 
independent effects on ventilation, though SSRI s have not been shown to cause severe 
respiratory depression on their own.25-43 This supports the need for additional 
investigation on the effects of serotonergic drugs. Escitalopram is highly selective for the 
serotonin transporter, has low selectivity for serotonin receptors and muscarinic 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 23 of 79 
  
 receptors, and is widely prescribed, maki ng it a good candidate as a second SSRI to 
evaluate in this study. 
The previous study evaluated effects on ventil ation over 5-days of dosing. SSRIs take 
approximately 3 weeks to reach maximal ther apeutic effect, which correlates with the 
time required for pre-synaptic inhibitory  serotonergic receptors to desensitize.44-46 SSRI 
effects on ventilation in the proposed study w ould be evaluated for a similar period of 
time to confirm if effects on ventilation persist under steady state conditions.   
Finally, an additional modifi cation in the proposed study will be the assessment of 
hypercapnic ventilation under hype roxic and hypoxic gas levels  using a modified Read 
rebreathing approach referred to as Duffin rebreathing. One limitati on of the rebreathing 
procedure from the previous study design is  all measurements are performed under 
hyperoxic conditions, which can have independent  effects on ventilation. In addition, the 
data cannot necessarily be used to ex trapolate to the dynamic changes in PO 2 and PCO 2 
that occur during real-world drug-induced respiratory de pression when a patient is 
breathing room air. Duffin modified th e Read rebreathing method to include 1) 
hyperventilation (primarily thr ough deep breathing) prior to rebreathing to achieve an end 
tidal PCO 2 or approximately 20-25 mm Hg prior to  rebreathing, 2) maintaining an isoxic 
end tidal PO 2 during rebreathing, and 3) repeating re breathing at 2 different isoxic end 
tidal PO 2 levels (i.e., at 150 mm Hg and 50 mm Hg). These modifications, which have 
been used by investigators for decades, allo w for critical physiol ogical measurements and 
thresholds to be captured that can then be us ed to model the effects of drugs when there 
are dynamic changes in PO 2 and PCO 2, such as during a real-world opioid overdose.47-52 
 
2. STUDY OBJECTIVES 
2.1 Primary Objectives 
x To study ventilatory effects of SSRIs (par oxetine or esc italopram) comb ined with 
oxycodone compared to oxycodone alone after 21 days of SSRI dosing.  
x To study ventilatory effects of SSRIs (p aroxetine or escitalo pram) compared to 
placebo after 20 days of SSRI dosing.   
2.2 Secondary Objectives  
x To compare ventilatory effects of SSRIs (paroxetine or escitalopram) combined 
with oxycodone compared to oxycodone alone after 6 and 12 days of SSRI 
dosing.  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 24 of 79 
  
 x To compare ventilatory effects of SSRIs (p aroxetine or escitalopram) compared to 
placebo after 5 and 11 days of SSRI dosing.  
2.3 Exploratory Objectives  
x To study whether paroxetine or escital opram affects the pharmacokinetics of 
oxycodone. 
x To evaluate differences in hypercapnic ventilatory response under hyperoxic or 
hypoxic rebreathing. 
x To study whether there is a direct pharmacodynamic inte raction between 
paroxetine or escitalopram and oxycodone. 
x To summarize additional pharmacokineti c parameters and pharmacodynamic 
measurements collec ted during the study. 
 
3. STUDY ENDPOINTS 
3.1 Primary Endpoints 
The following primary endpoints will be evaluated: 
x Minute ventilation at 55mm Hg end tidal CO 2 (VE55) under hyperoxic conditions 
on day 21 
x VE55 under hyperoxic conditions on day 20  
3.2 Secondary Endpoints  
The following secondary endpoints will be evaluated: 
x VE55 under hyperoxic conditions on days 6 and 12 
x VE55 under hyperoxic conditions on days 5 and 11 
3.3 Exploratory Endpoints  
The following exploratory PK parameters  will be determined for oxycodone and 
oxymorphone (days 6, 12, and 21) and paroxe tine, escitalopram, and escitalopram 
metabolites (days 2, 5, 6, 11, 12, 16, 20, and 21): 
x Maximum observed plasma concentration (C max) 
x Area under the plasma concen tration time curve (AUC) 
x Time at which C max occurs (T max) 
x Elimination rate constant (K el) 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 25 of 79 
  
 x Terminal half-life (t 1/2) 
x Accumulation ratio (for esci talopram and paroxetine) 
Additionally, the following exploratory PD markers may be evaluated:  
Ventilation and Cardiovascular Assessments:  
x During rebreathing stage 
o VE55  (minute ventilation at th e 55mm Hg end tidal CO 2 point) 
o Baseline minute ventilation  when end tidal PCO 2 is less than the 
ventilatory recruitment th reshold (represents non-chemoreflex drives to 
breathe) 
o Ventilatory recruitment threshold  (end tidal PCO 2 above which minute 
ventilation starts to increase linearly  with further increases in end tidal 
PCO 2) 
o Slope of the minute ventilation / en d-tidal partial pressure of carbon 
dioxide (end-tidal PCO 2) regression line that reflects the increase in 
minute ventilation relative to the increase in end tidal PCO 2 (represents 
chemoreflex sensitivity)  
o Extrapolated ventilation recruitment threshold  (intersection with X axis) 
x During relaxation stage 
o Minute ventilation, tidal volume, re spiratory rate, end-tidal PCO 2, end-
tidal PO 2, oxygen saturation, and heart rate during the relaxation stage 
o Number of apneic events lasting > 10 s during the relaxation stage 
Pupillary Assessments  
x Maximum pupil diameter before constriction  
x Minimum diameter at peak constriction  
x Percent change between  min/max diameter  
x Latency of constriction   
x Average constriction velocity  
x Maximum constriction velocity  
x Dilation velocity after peak constriction  
x Time to reach 75% recovery  of maximum diameter  
Sedation scores   
x Ramsey Sedation Scale   
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 26 of 79 
  
 x Visual Analogue Scale   
ECG Assessments  
x Change from baseline in QTc,  PR, QRS, J-T peakC, Tpeak-Tend and heart rate. 
An exploratory endpoint is the pharmacoki netic/pharmacodynamic (P K/PD) relationship 
for study drugs when administered alone versus in combination. 
 
4. INVESTIGATIONAL PLAN 
4.1 Study Design 
This study will be a randomized, double blind, three period cr ossover study with 
approximately 25 healthy volunt eer participants. This study will include three 21-day 
treatment periods with a 3-w eek washout between each period. Each subject will be 
randomized to 1 of 6 treatment sequences (i.e., ABC, ACB, BAC, BCA, CAB, CBA). 
FDA will prepare the ra ndomization schedule. 
Table 4-1: Study Schedule  
 
 
 
Table 4-2: Study Treatments: 
 Participants will enter the clinic on a staggere d basis in cohorts of approximately five so 
that no more than five su bjects are undergoing rebreathi ng on any given day. Subjects 
will be staggered to allow for direct safe ty overview by medical staff during Duffin’s 
rebreathing.  
Participants will receive either placebo, paroxe tine, or escitalopram on days 1-21 for each 
period. Oxycodone will be administered on days  6, 12, and 21 of each period. Dosing of 
the study drugs will occur at time 0 on each da y. Oxycodone dosing will occur at 3 h so Day -1  Days 1-21 Days 22-42 Days  42-63 Days 64-84  Days 85-105 Day 106 
Check-in  Period 1 Washout Period 2  Washout  Period 3  Check-out 
Treatment  Day  
1-5 6 7-11 12 13-20 21 
A Placebo Placebo +  
10 mg oxycodone Placebo Placebo +  
10 mg oxycodone Placebo Placebo + 
10 mg oxycodone 
B 40 mg 
paroxetine  40 mg paroxetine 
+ 10 mg 
oxycodone 60 mg paroxetine 60 mg paroxetine 
+ 10 mg 
oxycodone 60 mg paroxetine 60 mg paroxetine 
+ 10 mg 
oxycodone 
C 20 mg 
escitalopram 20 mg 
escitalopram +  
10 mg oxycodone 30 mg 
escitalopram 30 mg 
escitalopram +  
10 mg oxycodone 30 mg 
escitalopram 30 mg 
escitalopram + 10 
mg oxycodone 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 27 of 79 
  
 that maximum concentration occurs for all drugs is at approximately the same time. 
Participants will also receive ondansetron 4 mg 30 min before oxycodone administration.  
Participants will be confined to the study c linic from Day -1 the morning of Day 22 for 
each period. There will be a three-week wa shout between each pe riod. Subjects will be 
discharged from the study after completion of all study procedures. If a subject 
discontinues from the study prematurely, all procedures scheduled for the end of the 
study will be performed. Meal  timing and components, ac tivity levels, and general 
conditions in the study clinic will be as similar as possible on the treatment days. 
Upon return to clinic, on Days 42 & 84, eligibility criteria to continue study participation 
will be reviewed (see Schedule of Events for criteria listed on Days 42 & 84), any 
changes in medical history (including conc omitant medications) will be documented. 
4.1.1 Risk/Benefit 
Subjects will be informed that participati on in a human clinical  pharmacology study like 
the present one cannot be of benefit to hea lthy volunteers. Neverthe less, the information 
from the physical examination, vital sign measurements, and ECG results may be shared 
with the subject’s personal physician if this  is the subject’s choice. Subjects will be 
informed that it is also their choice to in form their personal physician that they are 
participating in this research study. 
Subjects will be informed that  their contribution to the st udy is of major importance to 
agencies like the FDA to understand the potential for respirat ory depression with 
coadministration of SSRIs and opioids. Howeve r, since this is a study involving healthy 
volunteers, subjects will be informed that th ey have the option not to participate. 
Subjects will be informed that  opioids have a box warning fo r life-threatening respiratory 
depression. To mitigate potential events, s ubjects will undergo continuous pulse oximetry 
monitoring, there will be st opping rules for the treatment , rescue medications for 
oxycodone will be present, and a safety management plan for staff will be implemented 
during the study which includes a requirement to have  1:1 advanced cardiac life support 
staff to subjects in addition to  the study investigator.   
Subjects will be informed that they may be exposed to risks associated with the 
pharmacological properties of  the study drug and the study procedures. The following 
summary of potential AEs for the study drugs wi ll be provided to and discussed with the 
subjects: 
1. Oral oxycodone 5 mg IR tablets (up to 10 mg): The most common adverse events 
include typical opioid-related adverse reactions: nausea, c onstipation, vomiting, 
headache, pruritus, insomnia, dizziness, asthenia, agitation, a nxiety, hallucinations, 
nightmares, and somnolence. Serious a dverse reactions include: respiratory 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 28 of 79 
  
 depression, respiratory arre st, circulatory depression, cardiac arrest, hypotension, 
and/or shock.53 
2. Oral paroxetine 20 mg IR tablets (up to  60 mg): The most common adverse events 
include: somnolence, insomnia, agitation, tremor, anxiety, dizziness, constipation, 
nausea, diarrhea, dry mouth, vomiting, flat ulence, asthenia, erectile dysfunction, 
delayed ejaculation, vaginal paresthesia, itching, and discharge, yawning, infection, 
sweating, decreased appetite, nervousn ess, impotence, and libido decreased.54 
3. Oral escitalopram 10 mg ta blets (up to 30 mg): The mo st common adverse events 
include: insomnia, ejaculation disorder, drowsiness, impotence, nausea, sweating 
increased, fatigue, somnolence, decreased li bido, anorgasmia, headache, diarrhea, dry 
mouth, dizziness, constipation, and indigest ion. Additional adverse events include 
hypersensitivity reactions, seizures, syncope, QT interval prolongation, cardiac 
arrhythmias, enhanced clotting, and hepatic enzyme elevation.55  
4. Oral ondansetron 4 mg tablets given prio r to oxycodone for nausea/vomiting and 4 
mg IV as needed: The most common adve rse events include: diarrhea, headache, 
fever, malaise, fatigue, constipation, and hypoxia. Additional adverse events include: 
hypersensitivity reactions, including anaphyl axis and bronchospasm, QT interval 
prolongation and Torsade de Pointes, a nd serotonin syndrome (usually when 
prescribed with another serotoninergic medi cation such as select serotonin reuptake 
inhibitors and serotonin-norep inephrine reuptake inhibitors).56 
Selected doses of individual drugs are w ithin the FDA approved labeled doses or are 
doses that have been used in prior healthy participant studies for similar durations. As 
drug combinations are being st udied, the doses of oxycodone are less than that which has 
been used in prior studies in opioid na ïve healthy volunteers undergoing rebreathing5-6,11 
or other similar pro cedures (see below). 
x Oxycodone - A prior study of the effects of decreased ventilatory response to 
hypercapnia of oxycodone with and wit hout ethanol in opioid naïve healthy 
volunteers (young and elderly participan ts) used a dose of oxycodone 20 mg.5-6 
An additional ongoing study from these authors (unpublished) is using a dose of 
oxycodone 40 mg in opioid naïve healt hy volunteers. Our previous study 
(unpublished) used 10 mg oxycodone, whic h decreased ventilation approximately 
5 L/min from baseline and was well-tolerated by study participants with no 
discontinuations due to the selected dose. The present study will also use 
oxycodone 10 mg.  
x Paroxetine – Paroxetine will be administer ed 40 mg/day for 6 days and 60 mg/day 
for 15 days. This is within the maximum labeled dose of paroxetine (60 mg/day). 
The dose is higher than the typical starti ng dose of 20 mg/day that is titrated up 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 29 of 79 
  
 over 1-week intervals, however starting doses  up to 60 mg have been given safely 
to healthy volunteers.51 
x Escitalopram – Escitalopram will be admin istered at 20 mg/day for 6 days and 30 
mg/day for 15 days. This is above the ma ximal labeled dose of  escitalopram (20 
mg/day) but doses up to 30 mg/day have  been evaluated in a thorough QT study. 
The exposure with 30 mg is similar to th e steady state concentr ation expected in 
CYP2C19 poor metabolizers followi ng a therapeutic dose of 20 mg.55 
x Ondansetron – Ondansetron will be administe red as a single 4 mg oral dose in all 
treatment periods prior to administration of oxycodone and will be available as 4 
mg IV as needed for nausea and vomiting. A dose of 4 mg is less than the highest 
labeled dosing for other ondansetron indica tions (24 mg as a single dose or 8 mg 
twice a day).56  
The study drugs will not be administered to anyone who is pregnant. All women must 
take a pregnancy test before receiving any study drug in this study. All women of 
childbearing potential enrolled on this study will  be informed that th ey must use effective 
birth control methods (abstinen ce, intrauterine device, a nd contraceptive foam and a 
condom [i.e., double-barrier met hod]) during treatment. Subjects  will be informed that 
they must notify the investigator if they or their female partners become pregnant during 
the course of the study. If a subject becomes pr egnant, she will be informed that neither 
Spaulding Clinical Research nor the sponsor  will be responsible for the cost of any 
obstetric or related care, or for the child’s care. 
Subjects will be informed that insertion of an IV catheter ma y be required for blood 
sample collection and, during insertion of the catheter, soreness, brui sing, or infection at 
the insertion site are possible but unlikely. Subj ects will also be informed that dizziness 
and lightheadedness may occur during direct veni puncture, insertion of the IV catheter, or 
during blood collection. 
Subjects will be informed that they will be participating in the Duffin rebreathing 
SURFHGXUHZKHUHWKH\Z LOOEUHDWKHௗDK\SHUR[LF -hypercapnic (24% O 2, 6% CO 2, N2 
balanced) or hypoxic-hypercapnic (6% O 2, 6% CO 2, N2 balanced) gas mixture through a 
mask. They will be informed that this mixture of oxygen, carbon dioxide and nitrogen 
provided will be different than is  normally found in room air (21% O 2, 0.04% CO 2, N2 
balanced with minor amount s of other gasses). Subjects will be informed that the 
different gas concentrations, in  particular the higher level of carbon dioxide breathed in, 
may result in a feeling of needing to breathe  faster or more deeply. Subjects will be 
informed that this procedure has been us ed in many previous physiologic measurement 
studies and is non- LQYDVLYH'XULQJVFUHHQLQJVXEMHFWVZLOOEHVKRZQௗWKHUHEUHDWK LQJ
equipment and will be trained how to use it to understand if the procedure is tolerable.  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 30 of 79 
  
 Subjects will be informed that the confidentia lity of their data will be respected at all 
times according to state law, and the study personnel handling their study data are bound 
by confidentiality agreements. 
Subjects will be informed that extra precauti ons will be put in place, including required 
screening tests, that will limit the risk of  COVID-19. Precautions will be documented in a 
COVID-19 risk management plan. Subjects w ill be informed that despite the extra 
precautions there is still a risk of them contracting COVID-19. Any changes to the 
COVID-19 precautions (e.g., due to updated CDC recommendations or new testing 
becoming available) will be documented in the COVID-19 risk mitigation plan.  
Subjects will be informed that the study drug an d all tests, procedures , and visits required 
by the study are provided at no cost to them. If subjects become ill or physically injured 
because of participation in this study, they wi ll be informed that costs of treatment will 
not be covered by the sponsor. 
4.2 Selection of Study Population 
Subjects will be screened, and the data co llected will be reviewed by the principal 
investigator. Only those subjec ts who meet all the eligibilit y criteria will be enrolled. 
Approximately 25 healthy subjects are planned for enrollment. Every effort will be made 
to maintain an approximate 50:50 male-to-female sex distribution. 
4.2.1 Inclusion Criteria 
Subjects who meet all the follow ing inclusion criteria will be e ligible to participate in the 
study:  
1. Subject signs an IRB-approved written info rmed consent and privacy language as 
per national regulations (e.g., Health Insura nce Portability and Accountability Act 
authorization) before any study-re lated procedures are performed.  
2. Subject is a healthy, non-sm oking man or woman, 18 to 50 years of age, inclusive, 
who has a body mass index of 18.5 to 33.0 kg/m2, inclusive, at Screening. 
3. Subject has normal medical hi story findings, clinical labor atory results, vital sign 
measurements, pulse oximetry, 12-lead ECG results, and physical examination 
findings at screening or, if abnormal, the abnormality is not considered clinically 
significant (as determined and documente d by the investigator  or designee). 
4. Subject must have a negative test result fo r alcohol and drugs of abuse at screening 
and check-in days.  
5. Subject must test negative for severe acu te respiratory syndr ome corona virus 2 
(SARS-CoV-2) by a rapid antigen test at check-in for all study periods. If a 
subject’s test comes back as in valid, the test can be repeated. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 31 of 79 
  
 6. Female subjects must be of non-childbear ing potential (confirmed with follicle-
stimulating hormone levels > 40 mIU/mL) or , if they are of childbearing potential, 
they must: 1) have been strictly abstinen t for 1 month before check-in (Day -1) and 
agree to remain strictly abstinent for th e duration of the study and for at least 
1month after the last app lication of study drug; OR 2) be practicing 2 highly 
effective methods of birth c ontrol (as determined by the investigator or designee; 
one of the methods must be a barrier tec hnique) from at least 1 month before check-
in (Day -1) until at least 1 m onth after the end of the study.  
7. Male subjects must agree to practice 2 hi ghly effective methods of birth control (as 
determined by the investigator or design ee) from at least 1 mo nth before check-in 
(Day -1) until at least 1 month af ter the last dose of study drug. 
8. Subject is highly likely (as determined by the investigator) to comply with the 
protocol defined procedures and to complete the study. 
4.2.2 Exclusion Criteria 
Subjects who meet any of the following excl usion criteria will not be eligible to 
participate in the study: 
1. Subject has used any pres cription or nonprescription dr ugs (including aspirin or 
NSAIDs and excluding oral co ntraceptives and acetaminophen) within 14 days or 5 
half-lives (whichever is l onger) or complementary and al ternative medicines within 
28 days before the first dose of st udy drug. This includes prescription or 
nonprescription ophthalmic drugs. 
2. Subject is currently particip ating in another c linical study of an investigational drug 
or has been treated with a ny investigational dr ug within 30 days or 5 half-lives 
(whichever is longer) of the compound. 
3. Subject has used nicotine-c ontaining products (e.g., ci garettes, cigars, chewing 
tobacco, snuff, electronic ci garettes) within 6 weeks of Screening. Subjects must 
refrain from using thes e throughout the study. 
4. Subject has consumed alcohol , xanthine containing products  (e.g., tea, coffee, cola), 
caffeine, grapefruit, or grapefruit juice with in 24 h of check-in. Subjects must refrain 
from ingesting these throughout the study.  
5. Subject has a history or evid ence of a clinically signif icant disorder, condition, or 
disease (e.g., cancer, human immunodeficiency virus [H IV], hepatic or renal 
impairment) that, in the opinion of the i nvestigator would pose a risk to subject 
safety or interfere with the study eval uation, procedures, or completion. This 
includes subjects with any underlying medi cal conditions that put subjects at 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 32 of 79 
  
 increased risk of severe illness from C OVID-19 based on the Centers for Disease 
Control and Prevention (CDC) guidelines. 
6. Subject has any signs or symptoms at scr eening or check-in of any study periods that 
are consistent with COVID-19. Per curre nt CDC recommendations this includes 
subjects with the symptoms cough or shortness of breath or difficulty breathing, or at 
least two of the following symptoms: fever,  chills, repeated shaking with chills, 
muscle pain, headache, sore throat or new loss of taste/smell. In addition, the subject 
has any other findings suggestive of COVID-19 risk in the opinion of the 
investigator. 
7. Subject has known or suspected allergies or sensitivities to any study drugs. 
8. Subject has clinical labo ratory test results (hem atology, serum chemistry and 
urinalysis) at Screening or  period check-in that are out side the reference ranges 
provided by the clinical la boratory and considered c linically significant by the 
investigator. Clinical laboratory result s may be repeated once, as needed, for 
confirming results at Screen ing and period check-in.   
9. Subject has a positive test result at Screening for HIV 1 or 2 antibody, hepatitis C 
virus antibodies, or hepatitis B surface antigen. 
10. Subject is unable or unwilling to under go multiple venipunctures for blood sample 
collection because of poor tolerability or poor venous access. 
11. Female subject is currently pregnant or  lactating or was w ithin 3 months of 
enrollment. 
12. Subject has a history of opioi d or psychotropic drugs within  60 days of the start of 
the study. 
13. Subject has a history of asth ma that has required medication within the last five 
years. 
14. Subject has non-reactive or mishappen pupi l(s) or damaged orbit structure or 
surrounding soft tissue is edemat ous or has an open lesion. 
15. Subject has a Mallampati score of >2. 
16. Subject’s Duffin rebreathing data is of poor  quality or subject does not agree to 
remain clean-shaven for all days when  the Duffin rebreathing procedure is 
performed. 
17. Subject has a history of sleep  disorders, Panic disorders, Panic Attacks, Generalized 
Anxiety Disorder, or any associat ed DSM diagnosis or condition. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 33 of 79 
  
 18. Subject has a history of or  currently has hypoventilation syndrome or sleep apnea 
and is on non-invasive ventilation. 
19. Subject has a history of une xplained syncope, structural heart disease, long QT 
syndrome, heart failure, myocardial infarction, angina, unexplained cardiac 
arrhythmia, TdP, ventricular tachycardi a, or placement of a pacemaker or 
implantable defibrillator. Subjects will be al so excluded if there is a family history of 
long QT syndrome (genetically proven or  suggested by sudden death of a close 
relative to cardiac causes at a young age) or Brugada syndrome. 
20. Subject has a history of suicidal id eation or previous suicide attempts. 
 
21. Subject has a safety 12-lead ECG result at Screening or check-in at any study period 
with evidence of any of th e following abnormalities:  
x QTc using Fridericia correction (QTcF)>430 msec 
x  PR interval>220 msec or <120msec 
x QRS duration>110 msec 
x Second- or third-degree atrioventricular block 
x Complete left or right bu ndle branch block or inco mplete right bundle branch 
block 
x Heart rate <50 or >90 beats per minute 
x Pathological Q-waves (defin ed as Q-wave>40 msec) 
x Ventricular pre-excitation  
22. Subject has a skin condit ion likely to compromise ECG electrode placement. 
23. Any individual with breast implants.  
4.3 Screening Failures 
Subjects who sign and date the informed consen t form but who fail to meet the inclusion 
and exclusion criteria are defined as sc reening failures. A screening log, which 
documents the subject initials a nd reason(s) for screening failur e, will be maintained by 
the investigator for al l screening failures. A copy of th e log should be retained in the 
investigator’s study files. 
If a subject fails the screening process because of an abnormal laboratory result, they can 
receive a copy of the results upon request. Th e investigator will determine if follow-up 
for the abnormal laboratory result is needed  and will encourage the subject to follow-up 
with his or her personal physician as appropria te. All subjects will be informed as to the 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 34 of 79 
  
 reason(s) they are excluded fro m study participation, even if  follow-up is not required. If 
a subject fails the screening process becau se of a positive test result for human 
immunodeficiency virus or hepatiti s, the positive result will be reported to local health 
authorities as required by law. 
4.4 Termination of Study or Investigational Site 
4.4.1 Criteria for Termination of the Study 
The study will be completed as planned unless one of the following criteria is satisfied 
that requires early termination of the study. 
x New information regarding the sa fety or efficacy of the st udy drug(s) that indicates a 
change in the known risk prof ile for the study drug(s), such that the risk is no longer 
acceptable for subjects part icipating in the study. 
x Significant violation of Good C linical Practice (GCP) that compromises the ability to 
achieve the primary study objective or compromises subject safety. 
4.4.2 Criteria for Termination of the Investigational Site 
The study site may be terminated if the site  (including the inve stigator) is found in 
significant violation of GCP, the protocol, th e contractual agreement, or is unable to 
ensure adequate performance of the study. 
In the event that the sponsor elects to terminate the study or  the investigational site, a 
study-specific procedure for ea rly termination will be pr ovided by the sponsor; the 
procedure will be followed by the applicable investigational site during the course of 
termination. 
4.5 Criteria for Subject Withdrawal 
Subjects may withdraw from the study at any time at their own request, or they may be 
withdrawn by the investigator without th e approval of the subject based on the 
investigator’s clinical judgment. A subject is  not required to provide  a written request to 
withdraw from the study; howev er, a written request is required if a subject withdraws 
consent for his or her pe rsonal data to be used for study-related purposes. 
A subject may be discontinued for any of the following reasons: 
x AE: The subject has experienced an AE th at, in the opinion of the investigator, 
requires early termination. The appropriate electronic case report form (eCRF) must 
be completed for each AE. If a subject is  discontinued from the study due to an AE, 
the investigator is required to follow-up with the subjec t until the event resolves or 
becomes stable. If a subject dies during the study, the cause of de ath must be reported 
as a serious AE (SAE), with an out come of death noted in the eCRF. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 35 of 79 
  
 x Protocol Violation: The subjec t failed to meet protocol entr y criteria or did not adhere 
to protocol requirements, and continued part icipation poses an unnecessary risk to the 
subject’s health. 
x Withdrawal by Subject: The s ubject (or other responsible individual [e.g., caregiver]) 
wishes to withdraw from the study in  the absence of a medical need. 
NOTE: Withdrawal due to an AE shoul d not be recorded in the “voluntary 
withdrawal” category. 
x Study Terminated by Sponsor: The sponsor, I RB, FDA, or other regulatory agency 
terminates the study. 
x Pregnancy: The subject is  found to be pregnant. 
NOTE: If the subject is found to be pre gnant, the subject must be withdrawn 
immediately. The pregnancy will be followe d-up to term, and the outcome, including 
any premature termination will be recorded. All live births must be followed for a 
minimum of 30 days or until the first well-baby visit. 
x Other. 
NOTE: This category records withdrawal s caused by an accidental or a medical 
emergency, unblinding, and other rare cases. The specific reason s hould be recorded 
in the comment space of the eCRF. 
4.5.1 Handling of Withdrawals 
The investigator may terminat e a subject’s study participa tion at any time during the 
study when the subject meets th e criteria described in Sect ion 4.5. In addition, a subject 
may discontinue his or her participation wit hout giving a reason at  any time during the 
study. Subjects will be informed  that their participation in  the study is voluntary, that 
refusal to participate will invol ve no penalty or loss of benefi ts to which the subject is 
otherwise entitled, and th at the subject may discontinue participation at any time without 
penalty or loss of benefits to whic h the subject is otherwise entitled. 
Should a subject’s participati on be discontinued, the primary  reason for termination must 
be recorded. In addition, efforts should be ma de to perform all proc edures scheduled for 
the early termination visit. Any data and samp les collected before subject withdrawal will 
become the property of the sponsor. 
4.5.2 Replacement of Subjects 
Approximately 25 healthy subjects are planned for enrollment and will be randomized to 
1 of 6 treatment sequences.  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 36 of 79 
  
 4.6 Study Visits 
4.6.1 Recruitment 
Recruitment materials (e.g., internet, radio, an d print advertisements, social media posts) 
will be approved by the local IRB before telepho ne screening. The sponsor is responsible 
for registration of the stu dy on clinicaltrials.gov. Recruitm ent may not occur until the 
study is fully registered  on clinicaltrials.gov. 
4.6.2 Compensation 
Subjects will be offered paymen t for Screening; however, if the results of their alcohol 
and drug screening tests are positive, they will not be  compensated. Subjects who 
complete the entire study will receive paymen t according to the schedule provided in the 
informed consent form. No special incentiv es are offered. Final payment will not be 
released until all follow-up procedures have been completed and accepted by the 
investigator. 
If a subject chooses to withdr aw from the study prematurely, he or she will only be 
compensated for completed days . If subjects are withdrawn fo r medical reasons or if the 
study is halted temporarily or permanen tly, the subjects will receive compensation 
proportional to the time spent in the study. No compensation will be provided if a subject 
is dismissed from the study for noncomplian ce (e.g., improper conduct, ingesting alcohol 
and/or drugs [including recr eational drugs], tampering wi th the study drug, consuming 
any prohibited foods  or beverages). 
If subjects are required to stay  in the clinic for a longer period for sa fety reasons, they 
will be compensated at a rate proportional to  the entire compensation for the study. If a 
subject becomes ill or physically injured becau se of participation in  this study, the subject 
will be referred for treatment. 
4.6.3 Screening  
The following procedures and assessments will be performed at Screening (Day -28 to -
2): 
x Obtain informed consent/HIPAA authorizati on. The informed consent process will be 
performed by a clinical research nurse in a private room. The subject will be given 
unlimited time to ask questions  regarding study participati on, and each subject will be 
questioned to ensure their understanding. 
After informed consent is obtained: 
x Review inclusion/exclus ion criteria to confirm subject eligibility 
x Record demographic information 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 37 of 79 
  
 x Measure height, weight, and calculate body mass index 
x Perform serology screening (HIV anti gen/antibody [Ag/Ab] Combo 1/2, HepC 
antibody, HBsAg) 
x Record medical history 
x Perform alcohol and drug screening (am phetamines, barbiturates, benzodiazepines, 
cannabinoids, cocaine, alcohol, opia tes, phencyclidine, propoxyphene, and 
methadone) 
x Perform urine cotinine test 
x Perform a serum pregnancy te st (female subjects only) 
x Perform FSH measuring (postmenopausal [i.e ., without menses for two years] female 
subjects only) 
x Record prior medications 
x Monitor for AEs 
x Perform clinical laborator y tests (hematology, serum ch emistry, and urinalysis) 
x Measure vital signs (blood pressure, heart ra te, respiratory rate, pulse oximetry, and 
oral body temperature) 
x Perform a safety 12-lead ECG 
x Perform a complete physical examination, including asse ssment of participant’s 
Mallampati score 
x Examine pupils for shape and reactivity 
x Perform Duffin’s rebreathing unde r hyperoxic and hypoxic conditions 
4.6.4 Study Periods 
This study will be a randomized, double bl ind, three period crossover study. This study 
will include three 21-day treatment periods with a 3-week washout between each period. 
Participants will be confined to the study c linic from day -1 until the first day of each 
washout period. There will be a three week  washout between each period. Subjects will 
be discharged from the study after completion of all study procedures. 
4.6.4.1  Check-In 
The following procedures and assessment s will be performed at Check-in [Day  -1] and 
when participants check back into the clinic after each washout period: 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 38 of 79 
  
 x Perform/review results from SARS -CoV-2 rapid antigen test  
x Review inclusion/exclus ion criteria to confirm subject eligibility 
x Review medical history 
x Perform alcohol and drug screening (am phetamines, barbiturates, benzodiazepines, 
cannabinoids, cocaine, alcohol, opia tes, phencyclidine, propoxyphene, and 
methadone) 
x Perform urine cotinine test 
x Perform a serum pregnancy test at a ll check-ins (female subjects only) 
x Admit subject to the study clinic 
x Randomization (after completion of check-i n procedures or just before dosing on 
Day 1 of each study period)  
x Record concomitant medications 
x Monitor for AEs 
x Perform clinical laborator y tests (hematology, serum ch emistry, and urinalysis) 
x Measure vital signs (blood pressure, heart ra te, respiratory rate, pulse oximetry, and 
oral body temperature) 
x Perform a safety 12-lead ECG (only at initial check-in of each study period) 
x Perform a comprehensive physical examination 
x Perform Duffin’s rebreathing procedur e under hyperoxic and hypoxic conditions 
x Collect whole blood sample for CYP2D6 genotype/phenotype (only at check-in for 
first study period) 
4.6.4.2  Treatment 
The following procedures and assessments wi ll be performed during the treatment period 
according to the Schedule of Events (Appendix A): 
x Monitor for AEs 
x Record concomitant medications 
x Perform clinical laboratory te sts at specified  time points 
x Administer study drug according to the ra ndomization schedule following all other 
pre-dose examinations and specimen collection 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 39 of 79 
  
 x Measure vital signs (blood pressure, heart ra te, respiratory rate, pulse oximetry, and 
oral body temperature). If vital signs are scheduled at the sa me time as another event, 
vital signs will be measured after the ECG, but before blood sample collection 
x Perform safety 12-lead ECGs at timepoi nts specified in Section 4.7.2.4. If scheduled 
for the same time, safety 12-lead ECGs w ill always be performed before vital sign 
measurement and blood sample collection 
x Perform pulse oximetry monitoring as specifi ed in Appendix A – Schedule of Events 
x Perform rebreathing assessments followi ng Duffin’s rebreathing procedure at 
timepoints specified in Section 4.7.2.1. Prep aratory steps for the Duffin Rebreathing 
procedure (i.e., relaxation, hyperventilation)  should begin prio r to the scheduled 
sample time. Timing of sample collection is planned so that the PD assessment begins 
at the specified time and a 3- to 15-minute window is pl anned for completion of the 
procedure. 
x Perform pupillary assessments as specifie d in Appendix A – Schedule of Events 
x Perform sedation assessments as describe d in Section 4.7.2.3 (Ramsey Sedation Scale 
and Visual Analogue Scale) 
x Collect PK blood samples (6 mL) at timepoints specified in Section 4.7.1.1 
4.6.4.3  Washout 
After each period, there will be  a three week washout period. Prior to discharge for each 
washout period, the following pr ocedures will be performed: 
x Record concomitant medications 
x Monitor for AEs 
x Perform targeted physical exam 
x Measure vital signs (blood pressure, heart ra te, respiratory rate, pulse oximetry, and 
oral body temperature) 
x Collect PK blood samples (6 mL) at timepoints specified in Section 4.7.1.1 
x Pre-discharge sedation assessment 
When subjects check-in after each washout  period, the procedures and assessments 
specified in Section 4.6.4.1 will be performed. 
4.6.4.4  Discharge (or Early Termination) 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 40 of 79 
  
 The following procedures and assessments wi ll be performed before a participant is 
discharged at the end of the study or at early termination: 
x Record concomitant medications 
x Monitor for AEs 
x Measure height, weight, and calculate body mass index 
x Perform clinical laborator y tests (hematology, serum ch emistry, and urinalysis) 
x Measure vital signs (blood pressure, heart ra te, respiratory rate, pulse oximetry and 
oral body temperature) 
x Collect PK blood samples (6 mL) at the t imepoints specified in  Section 4.7.1.1 (only 
day 21 of each study period) 
x Assess for pre-discharge sedation 
x Perform a safety 12-lead ECG  
x Perform a complete physical examination 
x Discharge subject from the study clinic after completion of all study procedures 
4.7 Study Procedures 
4.7.1 Pharmacokinetic Assessments 
4.7.1.1  Pharmacokinetic Sample Collection  
Pharmacokinetic blood samples will be coll ected on the following days and at the 
approximate times fo r each study period: 
x Day 5, 6, 11, 12, 20, and 21: 0 (pre-dose), 3, 4, 5, 8 hr (and 24 hrs for Day 6, 12, 
and 21) 
x Day 2 and 16: 0 (pre-dose), 2, 3, 4, 5, 6, 8, 12, 24 hr 
Blood samples will be collected by direct veni puncture or by inserting an IV catheter. 
There will be a total of 51 PK samples pe r participant for each study period (Total of 153 
PK samples per participant for the entire study duration). 
Each blood sample will be labeled with s ubject number, study number, study day, time 
point, event, and a barcode that matc hes that belonging to the subject. 
Collection of the PK samples on the ECG colle ction days (Days 2 a nd 16 of each period) 
will be time-matched to the ECG extractions; th erefore, the subjects will be supine for 
approximately 10 minutes before the defined time points and for a pproximately 5 minutes 
after for ECG extraction/PK sa mple collection. The PK sample  will be collected after the 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 41 of 79 
  
 ECG extraction to avoid changes in autonomic  tone associated with the psychological 
aspects of blood collection and the reduc tion in blood volume subsequent to blood 
collection. A 5-minute window for PK sample collection is allowed after the ECG 
extraction window.  
4.7.1.2  Pharmacokinetic Specimen Handling 
The PK blood samples (6 mL each) will be  collected into tubes containing K 2EDTA, 
inverted several times to mix the blood with the anticoagulant, and pl aced in an ice bath. 
Within 30 minutes of collection, the samples will be centrifuged for 10 minutes, at 3000 
RCF, at 4°C, by a study team member. 
The plasma will be separated using a disposable  plastic pipette and equally aliquoted into 
duplicate cryotube vials labeled as Aliquot  A (primary) and Aliquot B (backup). The 
plasma samples will be appropr iately labeled and stored froze n at -70°C or below within 
30 minutes after aliquoting until shipment. Temperature monitoring logs should be 
maintained and accessible for re view by the study monitor.  
The Aliquot A samples (primary) will be ship ped first, on dry ice, to the bioanalytical 
laboratory at FDA for processing when request ed by the sponsor. The Aliquot B samples 
(backup) will be held for a second shipment  after completion of all Aliquot A sample 
shipment(s) and the timing of the Aliquot  B shipment will be communicated by the 
sponsor. None of the PK blood samples will be stored at the clinical  facility for future 
use. 
4.7.1.3  Pharmacokinetic Parameters 
The following exploratory PK parameters  will be determined for oxycodone and 
oxymorphone (days 6, 12, and 21) and paroxe tine, escitalopram, and escitalopram 
metabolites (days 2, 5, 6, 11, 12, 16, 20, and 21): 
x Maximum observed plasma concentration (C max) 
x Area under the plasma concen tration time curve (AUC) 
x Time at which C max occurs (T max) 
x Elimination rate constant (K el) 
x Terminal half-life (t 1/2) 
x Accumulation ratio (for esci talopram and paroxetine) 
4.7.2 Pharmacodynamic Assessments 
4.7.2.1  Duffin Rebreathing Assessments 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 42 of 79 
  
 Training on the Duffin’s rebreathing procedure will be performed to exclude any subjects 
who cannot tolerate the procedure.   
During Duffin’s rebreathing procedure, subjects will be placed in an upright position (90o 
angle) on a bed and connected to the respirat ion measurement set up. Subjects will wear a 
facemask and breathe from a pr e-filled rebreathing bag cont aining approximately 5 L of 
either a hyperoxic-hypercapnic (24% O 2, 6% CO 2, N2 balanced) or hypoxic-hypercapnic 
(6% O 2, 6% CO 2, N2 balanced) gas mixture. During this study, subjects will be asked to 
breath room air for 5 minutes (relaxation stag e) and then to hyperventilate (primarily 
through deep breathing) room air voluntarily for 5 minutes  (hyperventilation stage). 
Thereafter, subjects will be switched to th e rebreathing bag and perform rebreathing 
assessments at one of the 2 different isoxic end tidal PO 2,  i.e., 150 mmHg or 50 mmHg. 
The isoxia at 150 mmHg or 50 mmHg end-tidal PO 2 will be maintained by providing a 
computer controlled flow of 100% O 2 to the rebreathing bag.   
Subjects will perform one hype roxic and one hypoxic rebreathi ng procedure at check-in 
of each study period and a total of 4 rebrea thing procedures (three hyperoxic and one 
hypoxic) each day on Days 5, 6, 11, 12, 20, a nd 21 of each study period. Rebreathing 
procedures will be performed while fasting and will occur at 0, 4, and 5 hours post-doses 
on assessment days (hyperoxic at 0, 4 and 5 hours; a hypoxic assessment will be 
performed after the 5 hour hyperoxic assessme nt). Participants can communicate to staff 
to discontinue an assessment due  to discomfort at any time. Additional considerations for 
discontinuing a rebreathing procedure are described in a separate SOP for the 
Rebreathing Procedure. 
Each rebreathing procedure (r elaxation, hyperventilation, and rebreathing) should take 
approximately 13-15 minutes. Data colle cted throughout the procedure includes 
ventilatory flow and volumes as well  as percent gas compositions of O 2 and CO 2, which 
are used to calculate multip le physiological variables.  
Data from the rebreathing procedure will be acquired using the Hans Rudolph 
SmartLabTM Data Acquisition System. Collected data  will be analyzed using separate 
statistical software. Interim data analyses  may be performed after each cohort of 
participants have completed. If reproducibi lity is acceptable and no procedural changes 
are needed, additional lead-in cohorts may not be enrolled. If any study procedure 
element changes are needed, they may be ma de and additional pa rticipants may be 
enrolled.  
The clock on the rebreathing recorder will be confirmed to be consistent with the study 
clock at the clinical site; this will be conf irmed on each study day. Preparatory steps for 
the Duffin’s rebreathing proce dure (i.e., relaxation, hypervent ilation) should begin prior 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 43 of 79 
  
 to the scheduled sample time. Timing of sample collection is planned so that the 
rebreathing assessment begins at the specified time. Additional details on the Duffin’s 
rebreathing procedure is desc ribed in a separate SOP.  
The following physiologic measurements will be  assessed multiple times throughout the 
study: 
x Minute ventilation 
x Tidal volume 
x Respiratory rate 
x End-tidal PCO 2  
x End-tidal O 2 
x Oxygen saturation (SpO 2) 
x Heart rate 
4.7.2.2  Pupillary Assessments 
At Screening, subjects will be evaluated to ensure they meet requirements necessary for 
pupillary assessments (e.g., pup ils are reactive an d not misshapen). During the study, a 
pupillometer (a hand-held optical scanner) will be used to measure pupil size and 
dynamics in response to a light stimulus. Pupillary assessment s will be performed before 
and after each rebreathing period (excep t not in between th e hyperoxic and hypoxic 
paired assessment) while the ambient light is ke pt to a consistent level. The rubber cup of 
the pupillometer will be placed on the right ey e. The actual data recording only takes 
seconds.   
4.7.2.3  Sedation Assessments 
The Ramsey sedation scale will be comple ted by an observer prio r to the start of 
rebreathing assessment. 
• Level 1: Patient awake, anxious and agitated or restless, or both 
• Level 2: Awake, cooperative, orientated, and tranquil 
• Level 3: Patient awake and responds to commands only 
• Level 4: Asleep, brisk response to ligh t glabellar tap or loud auditory stimulus 
• Level 5: Asleep, sluggish response to light  glabellar tap or loud auditory stimulus 
• Level 6: Asleep, no response to light gl abellar tap or loud auditory stimulus 
At the same time as performing the Ramsey se dation scale, a visual analog scale will be 
administered to subjects by having subjects mark on a 100 mm perpendicular line how 
sedated they are from ‘awake and alert’ to ‘very sedated’  (i.e. 0 and 100 on the scale, 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 44 of 79 
  
 respectively). The distance from the left end of the line to the perpendicular mark will be 
measured in mm. 
4.7.2.4  ECG Assessments 
ECG assessments will be perform ed on the following study days  and time of each study 
period: 
- Day 1: 0 (pre-dose) hr - Day 2 and 16: 0 (pre-dose), 2, 3, 4, 5, 6, 8, 12, 24 hr 
Ten second 12-lead ECG tracings with the most  stable heart rate and highest signal-to-
noise ratio will be extracted in at least 3 re plicates at ECG extraction time points during 
each treatment period. During all ECG extractio n periods subjects will be placed in a 
supine position. Three ECG extractions will  be performed for a baseline measurement 
before the first oral dose on day 1 of  each treatment period. The other ECG 
extractions/period time matched to the PK samp les will be obtained before the PK sample 
collection time. Subjects will be isolated (not able to see each other) in a quiet 
environment that is free from external stimuli. 
 
4.7.3 Safety Assessments 
Safety will be evaluated in terms of AEs, clinical laboratory re sults (hematology, serum 
chemistry, and urinalysis), vital sign m easurements (blood pressure, heart rate, 
respiratory rate, and oral body temperature) , safety 12-lead ECG results, and physical 
examination findings.  
4.7.3.1  Adverse Events 
4.7.3.1.1  Adverse Event Definitions 
An AE is defined as any unt oward and/or unintended sign, in cluding an abnormal clinical 
laboratory finding, symptom, or disease temporally associated with the use of a study 
drug, whether or not considered related to the study drug. Events or conditions that 
increase in frequency or seve rity during or as a consequen ce of use of a drug in human 
clinical trials will also be considered AEs. 
A treatment emergent adverse event (TEAE) is defined as an AE that  begins after study 
drug administration. 
An unexpected AE is any AE having a specific ity or severity not consistent with the 
current investigator’s broc hure for the study drug(s). 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 45 of 79 
  
 A serious adverse event (SAE) is defined as any AE occurring at any dose that meets the 
following criteria: 
x Results in death, 
x Is life threatening, 
x Requires hospitalization or prolonga tion of existing hospitalization, 
x Results in persistent or significant disability or incapacity, 
x Results in a congenital anomal y/birth defect due to expos ure prior to conception or 
during pregnancy, or 
x Is an important medical event that may not  meet the previous criteria but, based upon 
appropriate medical judgment, jeopardizes the subject or requires medical or surgical 
intervention to prevent one of the outcomes listed previously. 
4.7.3.1.2  Adverse Event Reporting 
The recording of AEs will begin after the su bject signs the informed consent form and 
will continue until discharge (or early termination). All AEs, whether serious or 
nonserious and whether or not related to the study drug, must  be recorded in the eCRF. 
Study subjects will be instru cted to warn study staff if he or she has any unexpected 
symptoms. In addition, all subjects will rece ive a reminder telephone call approximately 
24 h before Check-in. 
Any SAE (whether expected or unexpected) mu st be entered into the eCRF system and 
reported by email to the medical monitor or  designee using the SAE Reporting Form 
within 24 h of the investigator or study clinic sta ff becoming aware of the event. It is the 
responsibility of the investigator  to report all SAEs to the me dical monitor, to provide the 
most complete report possible, and to assess each SAE for its relationship to the study 
drug. The investigator is res ponsible for obtaining follow-up information on all SAEs and 
submitting follow-up SAE data. Any unexpected SA Es must be reported promptly to the 
investigator’s IRB as pe r the IRB’s requirements. 
In the event of a fatal or life-threatening SAE, the spons or will notify the appropriate 
FDA authorities within 7 calendar days of rece ipt of the report. The sponsor will follow 
all 7-day alert reports with a written report wi thin 10 working days of receipt of the case. 
Serious AE cases that concern nonfatal, nonli fe-threatening events that are unexpected 
and at least possibly related to the study drug will be subm itted in writing to the FDA 
within 10 working days of receipt. 
Furthermore, any AEs that are not expect ed, occur at a higher frequency, or would 
require modification of the study protocol and/ or informed consent must be reported to 
the FDA within 10 working days. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 46 of 79 
  
 Adverse events that are assessed by the investig ator as possibly or probably related to the 
study drug will be followed until they resolve or stabilize. All SA Es will be followed 
until resolution. 
4.7.3.1.3  Assessment of Severity 
The investigator will assess the severity of each AE using the following scale: 
x Mild: The subject is aware of the AE but is still able to perform all activities; minimal 
or no medical intervention or therapy is required. 
x Moderate: The subject has to discontinue so me activities due to the AE; minimal or 
no medical intervention or  therapy is required. 
x Severe: The subject is incapacitated by th e AE and is unable to perform normal 
activities; significant medical intervention or  therapy is require d, and hospitalization 
is possible. 
4.7.3.1.4  Assessment of Causality 
The investigator will assess the causal relationship/relatedness of each AE to the study 
drug using the following scale: 
x Not Related: Onset of the AE has no reasonable temporal relationship to 
administration of the study drug, a causal relationship to adminis tration of the study 
drug is biologically implausible, or the even t is attributed to an  alternative etiology. 
x Unlikely Related: Onset of the AE has a reasonable temporal relationship to study 
drug administration and although a causal relationship is un likely, it is biologically 
plausible. 
x Possibly Related: Onset of the AE ha s a strong temporal relationship to 
administration of the study drug, cannot be e xplained by the subject’s  clinical state or 
other factors, and a causal relations hip is biologically plausible. 
x Probably Related: Onset of the AE show s a distinct temporal relationship to 
administration of the study drug that cannot  be explained by the subject’s clinical 
state or other factors, the AE is a known r eaction to the product or chemical group, or 
can be predicted by the product’s pharmacology. 
4.7.3.1.5  Pregnancy 
A serum pregnancy test will be performed for fe male subjects at the time points presented 
in the Schedule of Events (Appendix A). If a subject becomes pregnant while on the 
study, this should be reported immediately to the investigator, the subject will be 
withdrawn from the study and the medical mon itor and the subject will be instructed to 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 47 of 79 
  
 follow-up with his or her personal physician. All pregnancies are to be reported as an AE 
and followed for outcome. 
4.7.3.2  Clinical Laboratory Tests 
Clinical laboratory and diagnostic screening tests will be performed at the time points 
presented in the Schedule of Event and will be  collected in accordance with acceptable 
laboratory procedures. Clinical laboratory test ing will be performed by the clinical study 
contractor(s). The clinical laboratory tests th at will be performed are presented in Table 
4-3. Unused clinical laboratory test samp les will not be stored for future use. 
Table 4-3: Clinical Laboratory Tests & Diagnostic Screening Tests 
Hematolo gy Serum Chemistr y Urinal ysis 
Hematocrit 
Hemoglobin 
Platelet count Red blood cell count White blood cell count (with 
automated differential) Alanine aminotransferase 
Albumin 
Alkaline phosphatase Aspartate aminotransferase Bicarbonate Bilirubin (total, direct, and indirect) Blood urea nitrogen Calcium Chloride Creatinine (including calculated creatinine clearance) Glucose Lactate dehydrogenase Magnesium 
Phosphorus 
Potassium 
Sodium 
Total protein 
Uric acid Appearance 
Bilirubin 
Blood Color Glucose Ketones Leukocyte esterase Microscopic examination: red blood cells, white blood cells, epithelial cells, bacteria, crystals, and casts (if present) Nitrite pH Protein Specific gravity 
Urobilinogen 
Diagnostic Screening Tests:  
Serum  Urine  Whole Blood 
Serology (human 
immunodeficiency virus 
Ag/Ab Combo 1/2, hepatitis C virus antibody, and hepatitis B surface antigen) 
Female Subjects Only 
Human chorionic 
gonadotropin (for pregnancy) 
Follicle-stimulating 
hormone Drug screen including: 
amphetamines, barbiturates, 
benzodiazepines, cannabinoids, cocaine, alcohol, opiates, phencyclidine, propoxyphene, methadone, and cotinine Cytochrome P450 2D6 genotype (only 
performed at check-in for the first 
study period) 
 
Other 
SARS-CoV2 rapid anti gen test  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 48 of 79 
  
 Clinical laboratory results will be reviewed by the investigator or designee together with 
data in the eCRF. Any values outside the refe rence range will be evaluated for clinical 
significance. If a value is determined to be clinically significant, the subject will be 
instructed to follow-up with hi s or her personal physician. Th e investigator or designee 
may repeat the clinical laboratory tests if  deemed appropriate. The investigator will 
maintain a copy of th e laboratory accreditati on and the reference ra nges for the laboratory 
used. 
4.7.3.3  Vital Sign Measurements 
Vital signs (blood pressure, heart rate, respirat ory rate, and oral body te mperature) will be 
measured using an automated device at th e time points presented in the Schedule of 
Events (Appendix A). The subject should be  in a supine position, if possible, for a 
minimum of 5 minutes before vital signs are measured.  
4.7.3.1  Pulse Oximetry 
Continuous pulse oximetry mon itoring will be performed on rebreathing days (Days 5, 6, 
11, 12, 20, and 21 of each study period) specified in the Schedule of Events (Appendix 
A). 
4.7.3.2  Safety 12-lead Electrocardiograms 
Safety 12-lead ECGs will be obtained with  the subjects in the supine position for a 
minimum of 10 minutes before recording. ECGs will be overread by the Principal 
Investigator or designee (e.g., a medically qualified subinvestigat or). If an a bnormality is 
observed, the subject will be instructed to follow-up with his or her personal physician. 
4.7.3.3  Physical Examinations 
A complete physical examinati on will be performed at the time points presented in the 
Schedule of Events (Appendix A). 
The complete physical examination will include, but not be limited to, assessments of the 
head, eyes, ears, nose, throat, skin, thyr oid, nervous system, respiratory system, 
cardiovascular system, abdomen  (liver and spleen), lym ph nodes, and extremities. 
Height, weight (without shoes and wearing the lightest possibl e clothing), and calculation 
of body mass index will be perform ed at Screening and check-out. 
If a clinically significant a bnormality is observed upon physic al examination, the subject 
will be instructed to follow-up w ith his or her personal physician. 
4.7.4 Demographics and Medical History 
Demographic data (date of birth, gender, race, and ethnicity) will be collected at 
Screening. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 49 of 79 
  
 Each subject will provide a complete medical history at Screening that will be reviewed 
at Check-in. Specific information rela ting to any prior or existing medical 
conditions/surgical procedur es will be recorded in the subject’s eCRF. 
4.8 Study Treatments 
4.8.1 Dose Strategy  
Prior data with oxycodone alone using 20 mg  doses, showed signi ficant decreases in 
VE55 from baseline.5-6 Our previous study that administered 10 mg oxycodone showed 
approximately 5 L/min decrease with  oxycodone alone compared to baseline.20 The goal 
with the oxycodone dose is to have an effect  on the hypercapnic vent ilatory response with 
oxycodone alone, but not too high (for safety cons iderations) as it will be combined with 
a SSRIs that may also have effects on ventilation.  
Paroxetine dosing in labeling starts at 20 mg/d ay and allows titration up to a maximum of 
60 mg/day for obsessive compul sive disorder (panic disord er starts at 10 mg/day and 
allows titration up to 60 mg/day). Dosing to 60 mg/day will allow as sessment of effects 
on ventilation alone or combined with oxyc odone under clinically relevant exposures 
Escitalopram dosing in labeling starts at 10 mg/day and allows titration up to 20 mg/day 
for treatment of major depressive disorder a nd treatment of generaliz ed anxiety disorder. 
The study will administer up to 30 mg/day, whic h is above the maximal labeled dose of 
escitalopram (20 mg/day), but  doses up to 30 mg/day have been evaluated in a thorough 
QT study. Escitalopram exposure with 30 mg /day is similar to  the steady state 
concentration expected in CYP2C19 poor me tabolizers following a th erapeutic dose of 
20 mg/day. 
4.8.2 Treatments Administered  
For all drugs, standard drug doses or doses used  in prior studies in healthy participants 
will be used in this study. Multiple doses of  the assigned study drug will be administered 
to each subject during the treatment pe riod. Oxycodone, paroxetine, escitalopram, 
ondansetron, and placebo will be administered or ally. Subjects will co mplete each of the 
three treatments (A, B, and C):  
x Treatment A: Placebo on Days 1-5; Pl acebo + Oxycodone (10 mg IR) on Day 6; 
Placebo on Days 7-11; Placebo + Oxycodone  (10 mg IR) on Day 12; Placebo on 
Days 13-20; Placebo + Oxycodone (10 mg IR) on Day 21 
x Treatment B: Paroxetine (40 mg) on Days 1-5; Paroxetine (40 mg) + Oxycodone (10 
mg IR) on Day 6; Paroxetine (60 mg) on Days 7-11; Paroxetine (60 mg) + 
Oxycodone (10 mg IR) on Day 12; Paroxetine  (60 mg) on Days 13-20; Paroxetine (60 
mg) + Oxycodone (10 mg IR) on Day 21 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 50 of 79 
  
 x Treatment C: Escitalopram (20 mg) on Da ys 1-5; Escitalopram  (20 mg) + Oxycodone 
(10 mg IR) on Day 6; Escitalopram (30 mg ) on Days 7-11; Esc italopram (30 mg) + 
Oxycodone (10 mg IR) on Day 12; Esc italopram (30 mg) on Days 13-20; 
Escitalopram (30 mg) + Oxycodone (10 mg IR) on Day 21 
Paroxetine, escitalopram, or placebo will be administered at time 0 on each day. 
Oxycodone dosing will occur at 3 h on days 6, 12, and 21. Participants will also receive 
ondansetron 4 mg 30 min before oxycodone administration on days 6, 12, and 21. 
Study drugs will be administered by a clinical research nurse on the study clinic floor at 
the subject’s bedside. The pharm acist and investigator will be  available if needed during 
study drug administration. Oral study drugs will be administered with 240 mL of 
room-temperature water. 
4.8.3 Dose Selection and Schedule 
Oxycodone: The oxycodone dose is 10 mg IR. Oxycodone dose selection is based on 
previous published results where oxycodone was administered alone or in combination 
using rebreathing procedures in healthy vol unteers. Two studies by van der Schrier and 
others evaluated oxycodone 20 mg alone  or in combination with ethanol.5-6 Sedation 
levels in the ethanol study in particular, which included a higher dose of oxycodone and 
was performed in the young and elderly, were moderate and well addressed by mild 
stimulation of the subjects. Varying dose comb inations of oxycodone and morphine (total 
combined doses of 15 mg) have been sa fely evaluated using a similar system.7 Our 
previous study with oxycodone 10 mg IR show ed that small (approximately 5 L/min) but 
detectable effects on hypercapnic ventilation coul d be safely observed with this dose with 
minimal effects on baseline ventilation.20   
Paroxetine: The paroxetine dose is 40 mg IR for Days 1-6 and 60 mg IR for Days 7-21. 
Paroxetine dose selection was based on av ailable safety data from the original 
development program and to achieve sustained steady state exposures of  paroxetine at the 
highest approved paroxetine dose for at le ast one week before the day 20 and 21 
assessments.  Target dosi ng range for paroxetine is 20-60 mg/day depending on the 
indication. Initial starting doses  in labeling for general anxi ety disorder, social anxiety 
disorder, posttraumatic stre ss disorder, obsessive compul sive disorder, and major 
depressive disorder are 20 mg/day with dose increases of 10-mg/day made in intervals of 
1 week. Paroxetine has been administered at 30 mg/day for 30-days in healthy volunteers 
and up to 60-mg as a single  dose in healthy volunteers.51  
Escitalopram: The escitalopram dose is 20 mg  for Days 1-6 and 30 mg for Days 7-21. 
Escitalopram dosing in labeling starts at 10 mg/day and allows titration up to 20 mg/day 
for treatment of major depressive disorder a nd treatment of generali zed anxiety disorder. 
The study will administer up to 30 mg/day, whic h is above the maximal labeled dose of 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 51 of 79 
  
 escitalopram (20 mg/day), but  doses up to 30 mg/day have been evaluated in a thorough 
QT study for a comparable duration of time. Escitalopram exposure with 30 mg/day is 
similar to the steady state concentrati on expected in CYP2C19 poor metabolizers 
following a therapeutic dose of 20 mg/day.55 
Ondansetron: The ondansetron dose is 4 mg orally given 30 minutes before oxycodone 
administration. Up to two additional doses of IV ondansetron 4 mg can be given in a day 
for nausea/vomiting. The select ed ondansetron dose is less than the recommended dosing 
for labeled indications of nausea and vomiti ng associated with highly or moderately 
emetogenic cancer chemotherapy, radiotherapy, or postoperative nausea or vomiting.  
Naloxone: The naloxone dose is 0.4 mg admini stered intravenousl y, as needed, for 
respiratory depression as d eemed necessary by the inve stigator. Naloxone may be 
administered as a rescue medication fo r opioid-induced resp iratory depression.  
4.8.4 Method of Assigning Subjects to Treatment Sequence 
4.8.4.1  Randomization Process 
The project biostatistician will create the specific ations that will be used to generate the 
randomization schedule. The specifications w ill be based on the protocol requirements 
and appropriate statistical programming with  consideration for study design, number of 
treatments, number of subject s planned for enrollment, st ratification, and blocking. 
Based on these specifications, the project bi ostatistician (or designe e) will generate a 
dummy randomization schedule. The schedule is generated in R.  
The project biostatistician (o r designee) distributes the ‘dummy’ randomization schedule 
to specified personnel for revi ew. Any change (e.g., change in block size, change in 
stratification levels) that requi res an update to the specificati ons will reset this process. 
Minor changes (e.g., display formatting) will not require a change to the specifications. 
After the approval of the ‘dummy’ randomization schedule, the project biostatistician (or 
designee) transfers the program used to  generate the ‘dummy’ schedule to the 
randomization biostatistician (unblinded), who is an independent party and will not be 
participating in any programmi ng or statistical decisions for the study before breaking the 
blind. No transfer is necessary if the unbli nded randomization biosta tistician also created 
the ‘dummy’ randomization. 
The randomization biostatistician is responsib le for generating the final randomization 
schedule. The output is sent only to designate d unblinded recipients, who will maintain a 
secured digital and printed copy for their use. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 52 of 79 
  
 Archival of the programs and output is acco mplished by the creation of an encrypted, 
password-protected ZIP file c ontaining the program and output file(s). The ZIP file is 
copied to a secure storage drive on the sponsor’s site. 
Randomization will occur after informed consen t is obtained, either after completion of 
check-in procedures on Day -1 or just befo re dosing on Day 1. Approximately 25 healthy 
male and female subjects ar e planned for enrollment. Thus , a maximum of 25 subjects 
will be exposed to study drugs and procedures during the study.  
Enrolled subjects will be randomly assigned to  1 of 6 different treatment sequences 
consisting of the treatment groups  are presented in Table 4-2. 
All randomization information will be secure d and housed in a locked storage area, 
accessible only by the randomization personnel and the assigned pharmacist and his or 
her verifier. 
4.8.5 Identity of Study Drugs 
Oxycodone HCl (referred to throughout this do cument as oxycodone) is indicated for the 
management of pain severe enough to requi re an opioid analgesic and for which 
alternative treatments are inad equate. Oxycodone tablets are available as 5, 10, 15, 20, or 
30 mg strengths. The tablets are designed fo r immediate release of the drug where about 
60% to 87% of the drug reaches systemic circ ulation in comparison to a parenteral dose. 
Oxycodone HCl has a molecular weight of 351.82 and the molecular formula C
18H21NO 4ƔHCl. The physical form is a white odorless crystalline powder derived from 
the opium alkaloid, thebaine. Oxycodone dissolves in water (1 g in 6 to 7 mL) and is 
considered slightly soluble in alcohol.53 
Paroxetine HCl (referred to throughout this do cument as paroxetine) is indicated for the 
treatment of major depressive  disorder. Paroxetine HCl has a molecular weight of 374.8 
and the empirical formula is C 19H20FNO 3Ɣ+&OƔ 1/2H 2O. Paroxetine HCl is an odorless, 
off-white powder with a solubi lity of 5.4 mg/mL in water. Ta blets are available for oral 
administration in 10, 20, 30, and 40 mg strengths.48  
Escitalopram oxalate (referred  to throughout this document as escital opram) is indicated 
for acute and maintenance treatment of major depressive disorder a nd acute treatment of 
generalized anxiety disorder. Escitalopram is the pure S-enantiomer of the racemic 
bicyclic phthalane derivative citalopram. Esc italopram oxalate has a molecular weight of 
414.4 and the empirical formula is C 20H21FN 2OƔC2H2O4. Escitalopram oxalate is a fine, 
white to slightly-yellow powder and is freely so luble in methanol and dimethyl sulfoxide, 
soluble in isotonic saline soluti on, sparingly soluble in water a nd ethanol, sli ghtly soluble 
in ethyl acetate, and insoluble in heptane. Tablets are available for oral administration in 
5, 10, and 20 mg strengths.49 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 53 of 79 
  
 Ondansetron is indicated for the preventi on of nausea and vomiting associated with 
highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 
mg/m2, initial and repeat courses of mode rately emetogenic cancer chemotherapy, 
radiotherapy in patients receiving either to tal body irradiation, single high-dose fraction 
to the abdomen, or daily fra ctions to the abdomen, and prevention of postoperative 
nausea and/or vomiting. The empirical formula is C18H19N3O ƔHClƔ2H2O, 
representing a molecular we ight of 365.9. Ondansetron hyd rochloride dihydrate is a 
white to off-white powder that is soluble in water and normal saline. Ondansetron is 
available for oral administra tion as 4 and 8 mg tablets. Ondansetron hydrochloride is 
supplied as 20 mL multi-dose vials, 2 mg/mL.56 
Naloxone hydrochloride injection is i ndicated for the complete or partial reversal of 
opioid depression, including re spiratory depression, induced  by natural and synthetic 
opioids. Naloxone hydrochloride is also indicated for the diagnosis of suspected or 
known acute opioid overdosage. Naloxone hydroc hloride, an opioid antagonist, is a 
synthetic congener of oxymorphone, with a molecular weight of  363.84 and molecular 
formula of C19H21NO4 ƔHCl. Naloxone hydrochloride in jection may be diluted for 
intravenous infusion in 0.9% sodium chloride  injection or 5% de xtrose injection. The 
addition of 2 mg of naloxone hydrochloride in 500 mL of either solution provides a 
concentration of 0.004 mg/mL. Mixtures shoul d be used within 24 h. After 24 h, the 
remaining unused solution must be discar ded. Naloxone hydrochloride injection is 
supplied as 10 mL multi-dose vi als, 4 mg/10 mL (0.4 mg/mL).52  
Placebo capsules containing only cornstarch will be used as the placebo oral control in 
this study. 
4.8.6 Management of Clinical Supplies 
4.8.6.1  Study Drug Packaging and Storage 
The active study drugs will be obtained from co mmercial sources. Storage instructions 
for the active study drugs are as follows: 
x Oxycodone tablets should be stored at 25°C (77°F) w ith excursions permitted 
from 15° to 30°C (59° to 86°F) and should be protected  from moisture.53  
x Paroxetine tablets should be stored between 15° and 30°C (59° and 86°F).54 
x Escitalopram tablets shoul d be stored between 20° and 25°C (68° and 77°F); 
excursions permitted to 15° and 30°C (59° and 86°F).55 
x Naloxone hydrochloride injection should be stored at 20° to 25°C (68° to 77°F).58 
x Ondansetron tablets should be stor ed at 2° to 30°C (36° to 86°F).56  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 54 of 79 
  
 x Ondansetron injection should be stor ed at 20° to 25°C (68° to 77°F).59 
Placebo capsules will be supplied by the clin ical site, stored at  controlled room 
temperature (15°C to 30°C; 59°F to 86°F) , and protected from light and moisture. 
4.8.6.2  Study Drug Accountability 
Good clinical documentation practices will be  employed to record the receipt, storage 
conditions, accountability, and use or return  of the study drug. The study drug will be 
stored in a secure location with access to the study pers onnel who will be managing the 
storage, dispensing, and accountability of the study drug. 
Upon completion or termination of the study, final accountability review by the study 
monitor, and written authoriz ation from the sponsor , all unused and/or partially used 
study drug should be returned or destroyed at the study clinic. It is  the investigator’s 
responsibility to ensure that the sponsor has provided wri tten authorization for study drug 
disposal, the disposal process follows the study clinic’s standard  operating procedures, 
and appropriate records of the disposal are documented and maintained. No unused study 
drug may be disposed until fully accounted for by the study monitor (or designee). 
Documentation of unused study drug should in clude subject number, medication identity 
(medication #, period #), date, a nd quantity of study drug used. 
4.8.7 Blinding 
The study will be double-blind, and the blind wi ll be maintained through a randomization 
schedule held by the dispensing pharmacist. Treatments (escitalopr am, paroxetine, or 
placebo) will be over-encapsulated. The pharmacist (and designated staff member 
responsible for confirmation of study drug dos e) will be unblinded to subject treatment 
assignment; however, the pharmacist will not perform any study procedures other than 
study drug preparation and dispensing.  
 Additional details regarding blinding can be found in the Spaulding Blinding SOP which 
will be followed to ensure the blind is maintained throughout the study. 
4.8.7.1  Breaking the Blind 
The study drug blind will not be broken by the investigator or designee unless 
information concerning the study drug is n ecessary for the medical treatment of the 
subject. For unblinding a subject, the random ization information for unblinding can be 
obtained by contacting the dispen sing pharmacist. The sponsor  or medical monitor must 
be notified immediately if th e study drug blind is broken. The date, time, and reason that 
the blind was broken will be recorded in the source documents. If the blind is broken by 
the investigator or designee,  the study drug must be stoppe d immediately, and the subject 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 55 of 79 
  
 must be withdrawn from the study. Data or specimens already collected from subjects 
who discontinue prematurely and for whom the blind is broken will be made available for 
analysis if needed.  
4.8.8 Treatment Compliance 
At Screening, as part of the inclusion criteria, it will be confirmed that subjects are able to 
comply with the protocol-def ined procedure of injecting subcutaneous study drug. All 
doses of the study drug will be administered in the study clinic either under direct 
observation of or administered by clinic personnel and record ed in the eCRF. If a subject 
vomits after dosing, the event will be documen ted as an AE. The decision to replace any 
subject who vomits after dosing will be  made as described in Section 4.5.1. 
4.8.9 Prior and Concomitant Medications 
Subjects are prohibited from usi ng any prescription or nonpres cription drugs (including  
aspirin or NSAIDs and excluding oral cont raceptives and acetaminophen) within 14 days 
or 5 half-lives (whichever is  longer), or compleme ntary and alternative medicines within 
28 days before the first dose of study drug. Subjects are prohibite d from using any opioid 
or psychotropic drugs within 60 days of the start of the study. Subjects will be asked if 
they have used any of these substances and their responses will be recorded on the eCRF. 
Subjects are also prohibited fro m currently participating in another clinical  study of an 
investigational drug and may not have been tr eated with any invest igational drug within 
30 days or 5 half-lives (which ever is longer) of the compound. 
Subjects must be instructed not to take any medications , including over-the-counter 
products, without first consulting with the investigator. 
4.8.10  Subject Restrictions 
Subjects are not allowed to us e nicotine containing produc ts (e.g., cigarettes, cigars, 
chewing tobacco, snuff, elec tronic cigarettes) within 6 weeks before Screening. In 
addition, subjects are not allowe d to ingest alcohol, xanthi ne containing products (e.g., 
tea, coffee, chocolate, cola), caffeine, grapefruit, or grape fruit juice within  24 h of check-
in of all study periods. Subj ect must refrain from ingestin g these throughout the entire 
study. Subjects are not allowed to use aspirin or NSAIDs within 14 days before the first 
dose of study drug. Subjects will be  asked if they have used any of these substances and 
their responses will be recorded on the eCRF. 
Subjects must be able to tole rate a controlled, quiet study co nduct environment, including 
avoidance of music, television, movies, games,  and activities that may cause excitement, 
emotional tension, or arousa l during prespecified times (e.g., before and during ECG 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 56 of 79 
  
 extraction windows; before and during rebrea thing procedures) th roughout the duration 
of the study. 
Subjects must be willing to comply with study rules; atte mpting to void at specified 
times; remaining quiet, awake, undistracted, motionless, and supine during specified 
times; and avoiding vigorous ex ercise as directed throughout  the duration of the study. 
Standardized meals will be served at cons istent times relative to  dosing, and no food or 
fluids will be served containing caffeine. Subjects will fast during days with rebreathing 
assessments (i.e., Day 5, 6, 11, 12, 20, and 21 of each period) until after the last 
rebreathing assessment. On ECG collection da ys (Day 2 and 16 of each period) subjects 
will have fasted for at least 8 hours prior to drug administration. Subjects should only eat 
meals and snacks that are provided during period s of their stay in the study clinic, and 
should consume each meal that is served at  a reasonable pace (within 25 minutes). 
Outside of meal times, the s ubjects will only be allowed to intake water, which will be 
available ad libitum. 
Due to current precautions being taken for COVID-19, the following re strictions will be 
in place: 
x Subjects should be encouraged to wear mask s except when in a private room without 
anyone else present or for a limited tim e for a study procedure (e.g., study drug 
administration or eating) when instructed by staff.  
x Subjects must practice social distancing, which will include having a maximum of 2 
subjects per room for overnight stays and acces s to common areas will be per clinical 
research site standards. While subjects are in  house,  meals will be served per clinical 
research site standards. Subjects will spend most of their time in their rooms except 
for specified times for walking in the halls (with masks recommended). 
x Subjects must practice regular handwashing with soap and water, scrubbing hands for 
at least 20 seconds or with approved ha nd sanitizer as supp lied by study staff.  
Designated isolation rooms will be set up to se gregate any participant(s) that develop any 
symptoms of concern while housed in the uni t and COVID-19 testing will be done when 
deemed necessary by the Investigator. If new information becomes available, there could 
be other precautions that lead to additional restrictions that will be documented in the 
COVID-19 Risk Management Pl an and/or the study specifi c COVID-19 Procedure Plan. 
4.9 Statistical Methods 
4.9.1 Sample Size 
Approximately 25 healthy participants are pl anned for enrollment. A previous study (20 
participants) with paroxetine showed a decrease in 10.2 L/mi n in VE55 for paroxetine (40 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 57 of 79 
  
 mg) combined with oxycodone (10 mg) compared to oxycodone alone after 5 days of 
dosing with paroxetine. Similarly, there was a 9.3 L/min decrease in paroxetine compared 
to placebo after 4 days of dosing with paroxe tine. The standard devi ation in assessments 
was approximately 6.5 L/min. Assuming a simi lar effect size with paroxetine and 
escitalopram at day 20 and 21, the planned num ber of participants allows for a 40% drop 
out rate while mainta ining at least 90% pow er for separate one-sided tests at a 0.025 
significance level with the mul tiple primary endpoint. Study sa mple size did not consider 
secondary endpoints.  
4.9.2 Analysis Populations 
The rebreathing analysis population will includ e all subjects who completed at least one 
rebreathing assessment on any day or at any timepoint. Speci fic information on analysis 
populations for different pharmac odynamic measures will be de scribed in the Statistical 
Analysis Plan (SAP).   
A rebreathing assessment will be considered complete if the subject makes it through the 
entire procedure at a specific timepoint, if there are no identifiable issues with how the 
procedure was conducted, and if the VE55 regr ession converges.  Potential issues with 
how the procedure was conducted can included , but are not limited to, a leak from the 
system (e.g., substant ially decreasing O 2 during rebreathing or no evidence of an increase 
in CO 2 during rebreathing) or inaccurate read ings from the pneumotach (e.g., baseline 
minute ventilation readings less than 5 L/min).  
Subjects in this population will be used for the planned primary and secondary analyses 
related to evaluating drugs effe cts on the ventilatory response to hypercapnia.  If a subject 
does not contribute data from all treatments due  to early discontinuati ons or other reasons, 
only those comparisons where the subject ha s all required data will be performed. 
The PK population will include all subjects who receive study drug and have at least 
one estimable PK para meter after dosing. 
The safety population wi ll include all subjects who receive at least one dose of any of the 
study drugs. 
4.9.3 General Statistical Considerations 
All data will be presented in  data listings. Data from subjec ts excluded from an analysis 
population will be presented in the data listi ngs, but not included in the calculation of 
summary statistics. Demographic and baseline  characteristics will be summarized overall 
and by treatment for all subjects. 
4.9.4 Subject Disposition 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 58 of 79 
  
 The number of subjects who enroll in th e study and the number and percentage of 
subjects who complete each assessment will be presented. The frequ ency and percentage 
of subjects who withdraw or  discontinue from the study and the reason for withdrawal or 
discontinuation will be summarized. 
4.9.5 Demographics and Base line Characteristics 
Descriptive statistics will be used to summarize demographic and baseline subject 
characteristics. For continuous variables, the mean, median, sta ndard deviation (SD), 
minimum, and maximum values will be reported . For categorical (nominal) variables, the 
number and percentage of subjects (or observations) will be reported. 
4.9.6 Rebreathing Analyses 
4.9.6.1  Primary Analysis  
The primary objective is to study ventil atory effects of SSR Is (paroxetine or 
escitalopram) combined with an opioid ( oxycodone) compared to an opioid alone. The 
primary endpoint is VE55 unde r hyperoxic conditions on day 21.  
4.9.6.2  Data Analysis  
Minute ventilation and end-tidal pCO 2 (PETCO 2) data from the rebreathing stage of the 
Duffin rebreathing procedure wi ll be analyzed at the speci fied primary timepoints using 
piecewise linear regressions. The regressions will be used to predict VE55. VE55 when 
the SSRIs (paroxetine or escitalopram) are combined with oxycodone will be compared 
to VE55 with oxycodone alone.  
Multiple primary analyses are planned for each  drug. The first primar y analysis will be 
VE55 on day 21 at 5 h (hyperoxic) between oxycodone with paroxetine or escitalopram 
compared to oxycodone alone. The second primar y analysis will be VE55 on day 20 at 5 h 
(hyperoxic) between paroxetine or escitalopr am compared to placebo. Since Day 20 and 
21 are considered multiple primary endpoints,  comparisons will have an adjustment for 
multiplicity using a Bonferroni correction (eac h day will be tested at a 0.025 significance 
level). No adjustments will be ma de for separate testing of pa roxetine or escitalopram since 
the treatments are considered separa te interventions in the study.  
A linear mixed effects model will be developed using al l study data from hyperoxic 
assessments. Fixed effects will include treatment, period, sequence, and baseline VE55 
(i.e., VE55 obtained at 0 h on Day -1 of each treatment period).  Subject will be included 
as a random effect on the intercept.  If a subj ect’s baseline VE55 for a treatment period is 
not available, then the baseline value for that period will be calculat ed based on the median 
of all other baseline values for that subjec t from other study periods.  If a subject does not 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 59 of 79 
  
 have any completed baseline VE55 data, the su bject will be assigned a baseline VE55 equal 
to the median of the population.  
The Kenward-Roger approximation will be used to estimate denominator degrees of 
freedom for tests of  fixed effects. Normality  assumption will be verified using the Shapiro-
Wilke test for normality. Homogeneity of varian ces will be verified using Levene’s test. If 
the data in its original or transformed form does not satisf y assumptions for normality and 
homogeneity, a Wilcoxon signed-rank test will be  used for all comparisons rather than a 
linear mixed effect model. In the event that  the data does not satisfy assumptions for 
normality and homogeneity then a Wilcoxon signed -rank test will be used for comparisons.  
To demonstrate an effect when an SSRI (par oxetine or escitalopram) is combined with 
oxycodone compared to oxycodone alone, the u pper bound of the one-sided 97.5% CI of 
the least-square mean VE55 difference between treatments must not overlap 0 L/min.  
Similarly, to demonstrate an effect of paroxe tine (or escitalopram) compared to placebo 
the upper bound of the one-sided 97.5% CI of  the least-square mean VE55 difference 
between treatments must not overlap 0 L/min . Each comparison will be performed 
separately (i.e., þtrt’ asþparoxetine’ or þescitalopram’):  
ЬH0: VE55oxy+trt - VE55oxy  0 L/min 
ЬHA: VE55oxy+trt - VE55oxy < 0 L/min 
For secondary endpoints, effect s of SSRIs (paroxetine or escitalopram) with oxycodone 
compared to oxycodone alone will be performed on day 6 and day 12. 
As additional secondary endpoints, effects of  SSRIs (paroxetine or escitalopram) alone 
compared to placebo will be determined on da y 5 and 11 using the same model. Additional 
details on testing of ventilation secondar y endpoints is discussed in the SAP. 
4.9.7 Pharmacokinetic Analysis 
The PK parameters C max, AUC 0-t, Tmax, and K el will be summarized using descriptive 
statistics (number of subjects, geometric m ean, coefficient of vari ation [CV], mean, SD, 
median, minimum, and maximum) on Day 2, 5, 6, 11, 12, 16, 20 and 21 of each period 
for paroxetine, escitalopram, and escita lopram metabolites (Days 6, 12, and 21 for 
oxycodone and oxymorphone). The PK para meters will be analyzed using 
noncompartmental methods based on actua l sampling times. Geometric mean and 
individual concentration-time profiles will be presented in graphs. 
4.9.8 PK/PD Modeling 
A nonlinear-mixed effect pha rmacokinetic/pharmacodynamic model will be developed 
for VE55 and baseline-adjusted VE55 versus time for all treatments. The model will be 
developed using modeling software.  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 60 of 79 
  
 Additional details on PK/PD modeling will be discussed in a separate Modeling Analysis 
Plan. 
4.9.9 Electrocardiogram Analyses 
The QT interval will be co rrected for heart rate using Fridericia’s formula 
(QTc=QT/RR1/3). The J-T peak interval will be corrected for heart rate using the formula 
(J-T peakC = J-T peakC/RR0.58).60 Baseline will be the mean of the 3 predose ECG extractions 
of Day 1. 
Exposure-response analyses will be performed  for the change-from-baseline in QTc 
ǻ47FDQGFKDQJH  from baseline in other ECG m easurements (specified in ECG 
Analysis Plan), where the mean of the 3 pr edose ECG readings on Day 1 will be used as 
the Baseline. The concentration of the drug will be used as a covariate. Exposure-
response analysis will be done following most recent best practices in concentration-QTc 
modeling.61-62  
To assess the appropriateness of a linear mo del, normal QQ-plots for the residuals and 
plots of weighted residuals versus concen tration and versus fitted values will be 
produced. A model with a quadratic  term in concentration will be fitted and the quadratic 
term will be tested on the 2-sided 5% alpha le vel. In case of a significant quadratic term, 
nonlinear models, such as a log-linear model and an E max model, will be investigated and 
the primary model will be selected based on the Akaike Information Criterion and 
plausibility arguments.  
Unless the prespecified test procedure for linearity indicates ot herwise, the primary 
analysis will be based on a linear mixed eff ects model implemented in R software, with 
ǻ47FDVWKHGHSHQGHQWYDULDEOH GUXJSODVPDFRQ FHQWUDWLRQDQGE DVHOLQH47FDV
continuous covariates, treatment and time poi nt as categorical factors, and subject 
specific random effects for the intercept and slope. All post dose data will be used. The 
degrees of freedom for the model estimates will be determined by the Kenward-Rogers 
method. From the model, the slope (i.e., the regression parameter for the concentration) 
and the treatment effect will be estima ted together with 2-sided 90% CIs. 
The predicted mean placebo-adjust ed change from baseline QTc ( ǻǻQTc) at the 
observed geometric mean C max LHWKHSURGXFWZLWKW KHVORSHHVWLPDWHௗ ௗWUHDWPHQWHIIHFW
[ǻQTc active – ǻQTc placebo ]) and the 2-sided 90% CI of the estimate will be calculated.  
Additional details will be specified in the EC G Analysis Plan, including for analysis of 
other ECG measurements. 
 
4.9.10  Additional Analyses  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 61 of 79 
  
 4.9.10.1  Exploratory Respiratory Analyses  
Baseline minute ventilation, ve ntilatory recruitment thre shold, slope of the PCO 2-
ventilatory response curve, and the extrapolated  ventilatory recruitment  threshold will be 
calculated for each subject at each rebreath ing assessment. Data collected during the 
Duffin Rebreathing procedure will be used  to determine the slope of the minute 
ventilation / P ETCO 2 regression line.  Resting ventila tion, tidal volume, end-tidal PCO 2, 
and oxygen saturation will be determined using data from the relaxation portion of the 
Duffin Rebreathing procedure.  Apneic events lasting > 10 s will be determined using 
data collected during relaxation and prepar ation portion of the Duffin Rebreathing 
procedure.  An event is defi ned as the absence of inspirat ory flow (as measured by the 
pneumotachograph) for at least 10 s during this period.  These parameters will be 
summarized using descriptive statistics, and t ime courses summaries wi ll be generated for 
all treatment groups. Differences in hypercap nic ventilatory respons e under hyperoxic or 
hypoxic rebreathing at the 5-h t imepoint will be performed using paired t-test. These 
analyses will be considered hypothe sis-generating a nd exploratory. 
4.9.10.2  Pupillometry Analyses  
Maximum pupil diameter before constriction and dynamic pupillary measurements after a 
light stimulus will be measured before and after each rebreathing assessment (except not 
in between the hyperoxic and hypoxic paired assessment). These parameters will be 
summarized using descriptive statistics, and t ime courses summaries of  both scores will 
be generated for all treatment groups.  Pupilla ry changes will be compared to baseline 
measurements and between treatments to evalua te the effect of different interventions on 
pupillary changes.  In addition, time course pupillary changes will be compared to time 
course ventilatory changes across treatments  to evaluate concordance between these 
measures when subjects receive different drugs and drug combinations. These analyses 
will be considered hypothesis-generating and exploratory. 
4.9.10.3  Sedation Scores Analyses  
Ramsay Sedation Scale is an observer-based a ssessment of sedation that will be collected 
for each subject as during the relaxation period of each Duffin Rebreathing procedure.  In 
addition, subjects will be asked to provide their own assessment of sedation using the 
Visual Analog Scale during the same rela xation period. These are two measures for 
assessing an individual’s le vel of sedation and will provid e a subjective assessment of 
how sedation the subject is experiencing dur ing the study.  These parameters will be 
summarized using descriptive statistics, and t ime courses summaries of  both scores will 
be generated for all treatment groups. These analyses will be considered 
hypothesis-generating and exploratory. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 62 of 79 
  
 4.9.11  Safety Analyses 
4.9.11.1  Adverse Events 
All AEs will be coded using th e latest version of the Medi cal Dictionary for Regulatory 
Activities. The incidence of TEAEs, organize d by system organ class and frequency, will 
be summarized by seriousness, severity, rela tionship to treatment, and by treatment at 
onset of the TEAE. A detailed  listing of serious AEs and TEAEs leading to withdrawal 
will also be provided. 
4.9.11.2  Clinical Laboratory Tests 
Clinical laboratory results will be reviewed by the investigator or designee together with 
data in the eCRF. Any values outside the refe rence range will be evaluated for clinical 
significance. If a value is determined to be clinically significant, the subject will be 
instructed to follow-up with hi s or her personal physician. Th e investigator or designee 
may repeat the clinical laboratory tests if  deemed appropriate. The investigator will 
maintain a copy of th e laboratory accreditati on and the reference ra nges for the laboratory 
used. 
Clinical laboratory results (hematology, serum chemistry, and urinalysis) will be 
summarized using descriptive statistics ( number of subjects, mean, SD, minimum, 
median, and maximum). Clinical laboratory results will be classified as normal or 
abnormal, according to the reference ranges of the individual para meter. The number and 
percentage of subjects with abnormal laborat ory results will be pr ovided. No statistical 
testing will be performed on clinical laboratory data. 
4.9.11.3  Vital Sign Measurements 
Vital sign measurements and changes fro m Baseline will be summarized using 
descriptive statistics (numbe r of subjects, mean, SD, min imum, median, and maximum) 
by treatment and time point. 
4.9.11.4  Pulse Oximetry 
Continuous pulse oximetry will  be performed on rebreath ing days. Events requiring 
intervention from the staff or discontinua tion from the study will be recorded in 
appropriate logs. 
4.9.11.5  Safety 12-lead Electrocardiograms  
12-lead ECGs will be obtained with the subjects in the supine position for a minimum of 
5 minutes before recording. ECGs will be overread by a physician. If an abnormality is 
observed, the subject will be instructed to follow-up with his or her personal physician. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 63 of 79 
  
 4.9.11.6  Physical Examinations 
 Physical examination findings will be presented in a data listing, and abnormal physical 
examination findings will be recorded as AEs.  
4.9.11.7  Other Safety Data 
All concomitant medication usage and medicatio ns that changed in daily dose, frequency, 
or both since the subject provided informed consent will be summarized for each subject.  
4.9.12  Interim Analyses 
No interim analyses are planned.  
4.9.13  Missing Data 
Missing data will not be imputed. Data that are excluded from the descriptive or 
inferential analyses will be included in the subject data listings. This will include data 
from subjects not in the part icular analysis population, me asurements from unscheduled 
visits, or extra measurements that may arise from 2 or more analyses of the biofluid 
sample at the same time point. Details on th e handling of missing da ta will be further 
described in the SAP. 
4.10 Data Quality Assurance 
Completed eCRFs are required for each s ubject randomly assigned to treatment. 
Electronic data entry will be accomplished through the ClinSpark® remote electronic data 
capture system, which allows for on-site data  entry and data management. This system 
provides immediate, direct data transfer to the database, as well as immediate detection of 
discrepancies, enabling site coordinators to resolve and manage discrepancies in a timely 
manner. Each person involved with the study wi ll have an individua l identification code 
and password that allows for record traceability. Thus, the system, and subsequently any 
investigative reviews, can identify coordinato rs, investigators, and individuals who have 
entered or modified records. 
 
Furthermore, the investigator retains full re sponsibility for the accur acy and authenticity 
of all data entered into the electronic da ta capture system. The completed dataset and 
their associated files are the sole proper ty of the sponsor and should not be made 
available in any form to third parties, ex cept for appropriate governmental health or 
regulatory authorities, without writ ten permission of the sponsor. 
4.11 Data Sharing 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 64 of 79 
  
 De-identified subject-level data may be releas ed to other researchers (including through a 
data warehouse or as a part of a publicati on) to enable secondar y research. Additional 
secondary research may also be performed by the sponsor. 
 
5. ETHICAL CONSIDERATIONS 
5.1 Ethical Conduct of the Study 
This study will be performed  in accordance with the recommendations guiding 
physicians in biomedical re search involving human subjec ts adopted by the 18th World 
Medical Association General Assembly, Hels inki, Finland, 1964 and later revisions, as 
well as, United States Title 45 Code of Fe deral Regulations (CFR) Part 46 GCP, and 
International Council for Harmonisation (ICH) guideli nes describing technical 
requirements for registration of pharmaceuticals for human use. 
5.2 Institutional Review Board (IRB) 
The FDA Project Lead or investigator will pr ovide the designated IRB with all required 
documents, including the study protocol and informed consent form. The study will not 
be initiated until appropriate IRB approval is  obtained from the designated IRB. The 
investigator will provide the FDA Project Lead  with copies of the approval documents 
for the protocol, informed consent form, and all recruiting materials. The designated IRB 
will also receive copies of any original or amended information sheets or pamphlets 
given to the study subject in support of the informed consent process and any 
advertisements or other recruitment material . Such materials will not be employed in the 
study before approval by the designated IRB. 
 
Subjects will be informed that they have the right to contact the IRB or Office for Human 
Research Protections if they have any ques tions, concerns, complaints, or believe they 
have been harmed by the partic ipation in this research study  as a result of investigator 
negligence. Subjects will be given th e address and phone number of the IRB. 
6. ADMINISTRATIVE PROCEDURES 
6.1 Responsibilities of the Investigator  
The following administra tive items are meant to guide the investigator in  the conduct of 
the study but may be subject to change based on industry and government standard 
operating procedures, working practice doc uments, or guidelines. Changes may be 
reported to the IRB but will not result in protocol amendments. 
6.1.1 Form FDA 1572 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 65 of 79 
  
 The investigator will complete  and sign the Form FDA 1572. 
6.1.2 Adherence to Protocol  
The investigator agrees to conduct the study as outlined in this protocol in accordance 
with the ICH E6(R2) and all app licable guidelines and regulations. 
6.1.3 Reporting Requirements  
By participating in this study, th e investigator agrees to subm it reports of SAEs according 
to the timeline and method outlined in the protocol (Section 4.7.3.1.2). In addition, the 
investigator agrees to submit reports to th e IRB as appropriate. The investigator also 
agrees to provide the sponsor with an ade quate report shortly after completion of the 
investigator’s participation in the study. 
6.1.4 Source Documentation  
By participating in this study, the investigator agrees to ma intain adequate case histories 
for the subjects treated as part of the research  under this protocol. Th e investigator agrees 
to maintain accurate eCRFs and source documen tation as part of the case histories. 
6.1.5 Retention of Records  
The investigator agrees to keep the record s stipulated in this  protocol and those 
documents that include (but are not li mited to) the study-specific documents, 
identification log of all participating subjec ts, medical records, source worksheets, all 
original signed and dated informed consent forms, subject authorization fo rms regarding 
the use of personal health information (if separate from the informed consent form), 
copies of all eCRFs, query responses, and de tailed records of drug di sposition, to enable 
evaluations or audits from regulatory authorities, the sponsor, or its designees. 
Furthermore, ICH 4.9.5 requires the investigator  to retain essentia l documents specified 
in Section 8 of ICH E6(R2) un til at least 2 years after the last approval of a marketing 
application for a specif ied drug indication being investigated  or, if an application is not 
approved, until at least 2 years after the i nvestigation is discontinued and regulatory 
authorities are notified. In addition, ICH 4.9.5 states that the study records should be 
retained until an amount of time specified by applicable regulatory requirements or for a 
time specified in the clinical  study site agreement between the investigator and sponsor. 
Refer to the clinical study site agreemen t for the sponsor’s re quirements on record 
retention. The investigator s hould contact and receive wri tten approval from the sponsor 
before disposing of any such documents. 
6.1.6 Financial Disclosure and Obligations 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 66 of 79 
  
 The investigator is required to provide financial disclosure information to allow the 
sponsor to submit the complete  and accurate certification or disclosure statements 
required under 45 CFR 46. In addition, the inve stigator must provide  to the sponsor a 
commitment to update this info rmation promptly if any rele vant changes occur during the 
course of the investigation and for 1 year after the completion of the study. 
Neither the sponsor nor the study clinic is financially respons ible for further testing or 
treatment of any medical condi tion that may be detected dur ing the screening process. 
6.2 Confidentiality and Disclosure of Data 
All subjects will sign a HIPAA-compliant au thorization form containing the mandated 
core elements and requirements before par ticipation in this clinical study. The sponsor 
and designees affirm and uphold the principle of the subject’s  right to protection against 
invasion of privacy. Throughout th is study, a subject’s source da ta will only be linked to 
the sponsor’s electronic data  capture system database or  documentation via a unique 
identification number. As pe rmitted by all applicable la ws and regulations, limited 
subject attributes such as gender, age or date of birth, and subject ini tials may be used to 
verify the subject and accuracy of the subject’s unique id entification number. 
To comply with ICH Guidelines for GCP and to  verify compliance with this protocol, the 
sponsor requires that the inve stigator allow review of th e subject’s original medical 
records (source data or documents) by the study monitor, representatives from any 
regulatory authority (e.g., FDA), the sponsor’s  designated auditors, and the appropriate 
IRB. These medical records will include, but will not be limited to, clinical laboratory 
test result reports, ECG reports, admissi on and discharge summ aries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports. Access 
to a subject’s original medical records require s the specific authorization of the subject as 
part of the informed consent process. 
Copies of any subject source documents that are provided to the sponsor must have 
personally identifiable information removed (i.e., subject name, address, and other 
identifier fields not collected in the subject’s eCRF). 
Data will be maintained and backed up in th e electronic data capture system. All access 
to the data is protected by username and password, and each staff me mber and all sponsor 
staff will have separate access that requires a separate username and password. Access is 
only given to site staff and requested sponsor staff who ha ve completed the appropriate 
training. 
6.3 Subject Consent 
Written informed consent in compliance with 45 CFR 46 will be obtained from each 
subject before entering the study or perfor ming any unusual or nonroutine procedure that 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 67 of 79 
  
 involves risk to the subject. An informed  consent template may be provided by the 
sponsor to the study clinic. If any institution- specific modifications to study-related 
procedures are proposed or made by the study clinic, the consent should be reviewed by 
the sponsor or its designee or both before  IRB submission. Once reviewed, the consent 
will be submitted by the investigator to the IRB for review and approval before the start 
of the study. If the informed consent form is revised duri ng the course of the study, all 
active participating subjects must sign the revised form. 
Before enrollment, each prospective subject w ill be given a full explanation of the study 
and be allowed to read the approved info rmed consent form. The informed consent 
process will be performed by a clinical resear ch nurse in a private room. The subject will 
be given unlimited time to ask questions re garding study participat ion, and each subject 
will be questioned to ensure their understandi ng. Once the investigator is assured that the 
subject understands the implicat ions of participating in the study, the subject will be 
asked to give consent to participate in the study by signing the informed consent form. 
The investigator will provide a copy of the si gned informed consent fo rm to the subject. 
The original form will be maintained in the subject’s medical records at the site. 
6.4 Data Collection 
Full details of procedures for data collection and handling will  be documented in the data 
management plan, which is initiated with the final protocol receipt. The data management 
plan is a changing document that evolves over the course of the study and is finalized by 
database lock. 
6.5 Publications 
No information related to or generated by this  study will be released to the public until it 
has been reviewed by the sponsor. The sponsor shall own intellectual  rights for the data 
and analysis resulting from this study. Authorship on pub lications will be determined by 
standard journal requirements. 
 
7. STUDY MANAGEMENT 
7.1 Monitoring 
The sponsor or its designee will monitor the study to ensure that it is being conducted 
according to the protocol, GCP standards, a nd applicable region-specific requirements, 
and to ensure that study initiation, conduct, and closure are adequa te. The investigators 
and the study clinic staff will be expected to  cooperate fully with the study monitors and 
personnel or agents of the sponsor and be av ailable during monitori ng visits to answer 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 68 of 79 
  
 questions sufficiently and to provide any missing information.  The investigators and their 
institutions will permit direct access to source data/documents for study-related 
monitoring activities, audits, IRB re views, and regulatory inspections. 
During any on-site visits, the study monitor will:  
x Check and assess the progress of the study 
x Review all informed consent forms 
x Review study data collected 
x Conduct source document verification 
x Identify any issues and address their resolution 
x Verify that the fac ility remains acceptable 
x Conduct study drug accountability 
These monitoring activities will be done  in order to verify that the:  
x Data are authentic, accurate, and complete. 
x The safety and rights of the subjects are being protected. 
x The study is being conducted in accordan ce with the currently approved protocol 
(including any amendments), GCP, and a ll applicable regulatory requirements. 
In addition, the sponsor, designated auditors, and government inspectors must be allowed 
access to eCRFs, source documents, and other st udy files that may be required to evaluate 
the conduct of the study. 
7.2 Management of Protocol Amendments and Deviations 
7.2.1 Modification of the Protocol 
Any changes in this research activity, except those necessary to remove an apparent 
immediate hazard to the subjec t, must be submitted to the sponsor or designee and 
reviewed and approved by the local IRB be fore implementation. Amendments to the 
protocol must be submitted in writing to the investigator’s IRB for approval before 
subjects are enrolled in to an amended protocol. 
7.2.2 Protocol Violations and Deviations 
Any significant protocol deviations that the investigator or  study clinic st aff believes are 
of major importance (e.g., inco rrect randomizations, subject enrolled but not eligible) 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 69 of 79 
  
 should be reported to the sponsor and the investigator’s IRB as soon as possible. 
Significant protocol deviations  may include the following: 
x Deviations from the inclusion/exclusion criteria that may affe ct subject safety 
x Deviations (omission or delay) of  safety monitoring procedures 
x Deviations in the administration of the study drug 
x Deviations in obtaini ng informed consent 
All subjects who are enrolled and receive the study drug, regardless of whether they have 
a major protocol violation, must continue to  be followed for safety  for all follow-up study 
visits. 
 
  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 70 of 79 
  
 REFERENCE LIST 
1. FDA Drug Safety Communication found at https://www.fda.gov/dr ugs/drug-safety-
and-availability/fda-drug-safety-communi cation-fda-warns-about-serious-risks-and-
death-when-combini ng-opioid-pain-or . 
 
2. Xu, Lin, et al. (2021). "Effe cts of sedative psychotropic drugs combined with 
oxycodone on respiratory depression in the ra t." Clinical and translational science 
14.6: 2208-2219.  
3. Read, D. J. (1967). A clinical method for assessing the ventilatory response to carbon 
dioxide. Australas Ann Med, 16(1), 20-32.   
4. Rebuck A S. (1976). Measurement of ventilatory response to CO
2 by rebreathing. 
Chest. 70(1 Suppl), 118-21.   
5. van der Schrier R, Jonkman K, van Velzen  M, Olofsen E, Dr ewes AM, Dahan A, 
Niesters M. (2017a). An experimental st udy comparing the respiratory effects of 
tapentadol and oxycodone in healthy vol unteers. Br J Anaesth, 119(6), 1169-77. 
 
6. van der Schrier R, Roozekrans M, Olofsen E, Aarts L, van Velzen M, de Jong M, 
Dahan A, Niesters M. (2017b). Infl uence of Ethanol on Oxycodone-induced 
Respiratory Depression: A Dose-escalati ng Study in Young and Elderly Individuals. 
Anesthesiology, 126(3), 534-42.  
7. Ladd LA, Kam PC, Williams DB, Wright AW E, Smith MT, and Mather LE. (2005). 
Ventilatory responses of healthy subjects to  intravenous combinations of morphine 
and oxycodone under imposed hypercapnic and hypoxaemic conditions. British Journal of Clinical Pharmacology, 59(5), 524-535.  
8. Bourke DL and Warley A. (1989). The steady-state and rebreathing methods 
compared during morphine administrati on in humans. Journal of Physiology, 419, 
509-17.  
9. Sarton E, Teppema L, and Dahan A. (1999) . Sex differences in morphine-induced 
ventilatory depression reside within the peripheral chemoreflex loop. Anesthesiology, 
90, 1329-38.  
10. Rigg JR. Ventilatory effects and plasma c oncentration of morphine in man. Br J 
Anaesth. 1978;50(8):759-765.  
11. Webster, LR, Hansen E, Stoddard GJ, Rynders A, Ostler D, Lennon H. Ventilatory 
Response to Hypercapnia as Experimental  Model to Study Effects of Oxycodone on 
Respiratory Depression. (2022) Curr Rev Clin Exp Pharmacol. 17(1):72-80 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 71 of 79 
  
 12. Forster A, Gardaz JP, Sutur PM, and Gemp erie M. (1980). Respiratory depression by 
midazolam and diazepam. Anesthesiology, 53, 494-97. 
13. Power SJ, Morgan M, and Chakrabarti MK . (1983). Carbon dioxide response curves 
following midazolam and diazepam. British Journal of Anesthesia, 55, 837.-41.  
 
14. Cohen R, Finn H, Steen S. (1969). Effect of Diazepam and Meperidine, Alone and in 
Combination, on Respiratory Response to Ca rbon Dioxide. Anesthesia & Analgesia, 
48, 353–55.  
15. Geddes DM, Rudolf M, Saunders KB. (1976). E ffect of nitrazepam  and flurazepam 
on the ventilatory response to  carbon dioxide. Thorax, 31, 548–51. 
 
16. Bailey PL, Andriano KP, Goldman M, Stan ley TH, and Pace NL. (1986). Variability 
of the respiratory response to diazepam. Anesthesiology, 64, 460-65. 
17. Freye, E., Azevedo, L., & Hartung, E. (1985). Re versal of fentanyl related respiratory 
depression with nalbup hine. Effects on the CO
2-response curve in man. Acta 
Anaesthesiol Belg, 36(4), 365-374.   
18. Jarvis, D. A., Duncan, S. R., Segal, I. S ., & Maze, M. (1992). Ventilatory effects of 
clonidine alone and in the presence of  alfentanil, in human volunteers. 
Anesthesiology, 76(6), 899-905.   
19. Pavlin DJ, Coda B, Shen DD, Tschanz J, Nguyen Q, Schaffer R, Donaldson G, 
Jacobson RC, and Chapman CR. (1996). Effect s of combining propofol and alfentanil 
on ventilation, analgesia, sedation, and emes is in human volunteers. Anesthesiology 
84, 23-37. 
20. Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs 
and an Opioid on Ventilation. Found at https://clinicaltria ls.gov/ct2/show/[STUDY_ID_REMOVED] . 
 
21. Gaulton A, Hersey A, Nowotka M, et al. The ChEMBL database in 2017. Nucleic 
Acids Res . 2017;45(D1):D945-D954. 
 
22. PubChem Compound Summary for CID 43815, Paroxetine. National Center for 
Biotechnology Information; 2004. https://pubchem.ncbi.nlm .nih.gov/compound/Paroxetine . 
23. Richerson GB. (2004). Serotonergic neurons as carbon dioxide sens ors that maintain 
pH homeostasis. Nat Rev Neurosci. 5(6):449-461. 
 
24. Dahan A, Aarts L, Smith TW.(2010). Inciden ce, Reversal, and Prevention of Opioid-
induced Respiratory Depression. Anesthesiology ;112(1):226-238 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 72 of 79 
  
 25. Xu L, Krishna A, Stewart S, Shea K, Racz R, Weaver JL, Volpe DA, Pilli NR, 
Narayanasamy S, Florian J, Patel V, Matta MK, Stone MB, Zhu H, Davis MC, 
Strauss DG, Rouse R. (2021). Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat. Clin Transl Sci.  14(6):2208-2219. 
 
26. Bianchi AL, Denavit-Saubie M, Champagnat J. (1995). Central control of breathing 
in mammals: neuronal circuitry, membrane  properties, and ne urotransmitters. Physiol 
Rev.75(1):1-45. 
 
27. Mueller RA, Lundberg DB, Breese GR, Hedner J, Hedner T, Jonason J. (1982). The 
neuropharmacology of respiratory control. Pharmacol Rev. 34(3):255-285. 
 
28. Armijo JA, Florez J. (1974). The influen ce of increased brain 5-hydroxytryptamine 
upon the respiratory activity of cats. Neuropharmacology. 13(10-11):977-986. 
 
29. Florez J, Delgado G, Armijo JA. (1972). Adre nergic and serotonergic mechanisms in 
morphine-induced respiratory depression. Psychopharmacologia. 24(2):258-274. 
 
30. Meldrum MJ, Isom GE. (1981).  Role of  monoaminergic syst ems in morphine-
induced respiratory depression. Neuropharmacology. 20(2):169-175. 
 
31. Mueller RA, Lundberg D, Breese GR. (1980) . Evidence that respiratory depression 
by serotonin agonists may be exerte d in the central nervous system. Pharmacol 
Biochem Behav. 13(2):247-255. 
 
32. Annerbrink K, Olsson M, Hedner J, Erikss on E. (2010). Acute and chronic treatment 
with serotonin reuptake i nhibitors exert oppos ite effects on respiration in rats: 
possible implications for panic disorder. J Psychopharmacol. 24(12):1793-1801. 
 
33. Henderson DR, Konkle DM, Mitchell GS. (1999 ). Effects of serotonin re-uptake 
inhibition on ventilator y control in goats. Respir Physiol. 115(1):1-10. 
 
34. Morrison JL, Chien C, Riggs KW, Gruber N,  Rurak D. (2002). Effect of maternal 
fluoxetine administration on ut erine blood flow, fetal blood gas status, and growth. 
Pediatr Res. 51(4):433-442. 
 
35. Olsson M, Annerbrink K, Bengtsson F, He dner J, Eriksson E. (2004). Paroxetine 
influences respiration in rats: implicati ons for the treatment of panic disorder. Eur 
Neuropsychopharmacol. 
14(1):29-37. 
 
36. Robillard R, Saad M, Ray LB, BuJaki B, Douglass A, Lee EK, Soucy L, Spitale N, 
De Koninck J, Kendzerska T. (2021). Select ive serotonin reuptake inhibitor use is 
associated with worse sleep-related breat hing disturbances in individuals with 
depressive disorders and sleep co mplaints: a retrospective study. J Clin Sleep Med. 
17(3):505-513. 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 73 of 79 
  
 37. Bertani A, Perna G, Arancio C, Caldirola D,  Bellodi L. (1997).  Pharmacologic effect 
of imipramine, paroxetine, and sertralin e on 35% carbon dioxide hypersensitivity in 
panic patients: a double-blind, ra ndom, placebo-controlled study. J Clin 
Psychopharmacol. 17(2):97-101. 
 
38. Perna G, Bertani A, Gabriele A, Politi E, Bellodi L. (1997). Modification of 35% 
carbon dioxide hypersensitivity across one week  of treatment with clomipramine and 
fluvoxamine: a double-blind, randomi zed, placebo-controlled study. J Clin 
Psychopharmacol. 17(3):173-178. 
 39. Gorman JM, Browne ST, Papp LA, Martinez  J, Welkowitz L, Coplan JD, Goetz RR, 
Kent J, Klein DF. Effect of antipanic treatment on response to carbon dioxide. Biol 
Psychiatry. 1997;42(11):982-991. 
 
40. Bocola V, Trecco MD, Fabbrini G, Paladini  C, Sollecito A, Martucci N. (1998). 
Antipanic effect of fluoxetine measured by CO
2 challenge test. Biol Psychiatry. 
43(8):612-615. 
 41. Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. (2018). Drugs Most 
Frequently Involved in Drug Over dose Deaths: United States, 2011-2016. Natl Vital 
Stat Rep. 67(9):1-14. 
 
42. Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo F, Baser O, 
Murrelle L. (2015). Developmen t of a Risk Index for Se rious Prescription Opioid-
Induced Respiratory Depression or Overdos e in Veterans' Health Administration 
Patients. Pain Med. 2015;16(8):1566-1579. 
 
43. Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. (2018). Validation of a 
Screening Risk Index for Serious Pr escription Opioid-Induced Respiratory 
Depression or Overdose in a US Commerc ial Health Plan Claims Database. Pain 
Med. 19(1):68-78. 
 
44. Annerbrink K, Olsson M, Hedner J, Erikss on E. (2010). Acute and chronic treatment 
with serotonin reuptake i nhibitors exert oppos ite effects on resp iration in rats: 
possible implications for panic disorder. J Psychopharmacol. 24(12):1793-1801. 
 
45. Nutt DJ, Forshall S, Bell C, Rich A, Sa ndford J, Nash J, Argyropoulos S. (1999). 
Mechanisms of action of sele ctive serotonin reuptake inhibitors in the treatment of 
psychiatric disorders. Eur Neuropsychopharmacol. 9 Suppl 3:S81-86. 
 
46. Czachura JF, Rasmussen K. (2000). Effects of acute and chronic administration of 
fluoxetine on the activity of serotonergic ne urons in the dorsal raphe nucleus of the 
rat. Naunyn Schmiedebergs Arch Pharmacol. 362(3):266-275 
 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 74 of 79 
  
 47. Casey K, Duffin J, McAvoy GV. (1987). Th e effect of exercise on the central-
chemoreceptor threshold in man. J Physiol. 383:9-18. 
 48. Duffin J, McAvoy GV. (1988). The periphera l-chemoreceptor threshold to carbon 
dioxide in man. J Physiol. 406:15-26. 
 49. Mahamed S, Duffin J. (2001). Repeated  hypoxic exposures change respiratory 
chemoreflex control in humans. J Physiol . 534(Pt. 2):595-603. 
 50. Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, 
Camporesi EM. (1995). Naloxone-induced and spontaneous reversal of depressed 
ventilatory responses to hypoxia during and after continuous infusion of remifentanil 
or alfentanil. J Pharmaco l Exp Ther. 274(1):34-39. 
 51. Amin HM, Sopchak AM, Foss JF, Esposito BF, Roizen MF, Camporesi EM. (1994). 
Efficacy of methylnaltrexone versus nal oxone for reversal of morphine-induced 
depression of hypoxic ventilatory res ponse. Anesth Analg. 78(4):701-705 
 52. Dong TW, MacLeod DB, Santoro A, Augustin e Z, Barth S, Cooter M, Moon RE. 
(1985). A methodology to explor e ventilatory chemosensi tivity and opioid-induced 
respiratory depression risk. J A ppl Physiol. 2020;129(3):500-507. 
 
53. Oxycodone Package Insert obtained fr om DailyMed dated 10/13/2021. Found at 
https://dailymed.nlm.nih .gov/dailymed/lookup.cfm?setid=928227bf-89c5-4c64-9823-
0e84cc669388    
 
54. Oral Paroxetine Package Insert obtai ned from DailyMed dated 09/23/2021. Found at 
https://dailymed.nlm.nih .gov/dailymed/lookup.cfm?setid =ef3b5cbe-f9e1-c1ac-79da-
cfe14e3a7e7e   
 
55. Lexapro Package Insert obtained fro m DailyMed dated 09/20/2021. Found at 
https://dailymed.nlm.nih .gov/dailymed/drugInfo.cf m?setid=13bb8267-1cab-43e5-
acae-55a4d957630a   
 
56. Zofran Package Insert obtained from DailyMed dated 10/2017. Found at  
https://www.accessdata.fda.gov/drug satfda_docs/label/2017/020103s036,020605s020
,020781s020lbl.pdf   
 
57. Heydorn W.E (1999). Paroxetine: A review of its pharmacolo gy, pharmacokinetics, 
and utility in the treatment of variety of ps ychiatric disorders. Expert Opin Investig 
Drugs, 8(4), 417-41. 
 
58. Naloxone Package Insert obtained fro m DailyMed dated 03/20/2020. Found at 
https://dailymed.nlm .nih.gov/dailymed/drugInfo.cf m?setid=8cc25cf1-008c-4808-
baec-49f35a887fae   
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 75 of 79 
  
  
59. Ondansetron Package Insert obstained  from DailyMed dates 10/15/2021. Found at 
https://dailymed.nlm.nih .gov/dailymed/drugInfo.cf m?setid=fa8c2931-35a7-4b4b-
8be2-eda701b51079   
 
60. Johannesen, L., Vicente, J., Mason, J. W., Sa nabria, C., Waite-Labott, K., Hongm M., 
Strauss, D. G. (2014) Di fferentiating drug- induced multichannel black on the 
electrocardiogram: randomi zed study of dofetilide, quinidine, ranolazine, and 
verapamil. Clinical Pharmacol ogy & Therapeutics, 96(5), 549-558. 
 61. Garnett C, Bonate PL, Dang Q, Ferber G, Hu ang D, Liu J, Mehrotra D, Riley S, Sager 
P, Tornoe C, Wang Y (2018). Scientific white paper on concentration-QTc modeling. 
J Pharmacokinet Pharmacodyn, 45(3):383-397. 
 62. E14/S7B Questions and Answer s: Clinical and nonclini cal evaluation of QT/QTc 
Interval Prolongation and Proarrh ythmic Potential. Found at 
https://database.ich.o rg/sites/default/files/E14-S7B_QAs_Step4_2022_0221.pdf  
 
 
 
    
 
          
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
CONFIDENTIAL Page 76 of 79 
  
 8. APPENDICES 
Appendix A – Schedule of Events 
 

U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
 Appendix B – List of Abbreviations 
LIST OF ABBREVIATIONS 
Abbreviation Definition 
AE adverse event 
Ag/Ab antigen/antibody 
AUC  area under the concentration-time curve  
CDC Center for Disease Control 
CFR Code of Federal Regulations CI confidence interval 
C
max maximum observed concentration 
COVID-19 coronavirus disease of 2019 
CO 2 carbon dioxide 
CV coefficient of variation 
CYP cytochrome P450 
ECG electrocardiogram eCRF electronic case report form 
FDA Food and Drug Administration 
FSH follicle stimulating hormone 
GCP Good Clinical Practice 
HBsAg hepatitis B surface antigen 
HepC hepatitis C  
HIPAA Health Insurance Port ability and Accountability Act 
HIV human immunodeficiency virus 
ICH International Council for Harmonisation IR immediate release 
IRB Institutional Review Board 
IV intravenous 
J-T
peak early repolarization interval 
J-T peakC heart rate-corrected J-T peak interval 
ǻ--TpeakC change-from-baseline in J-T peakC 
ǻǻ--TpeakC placebo-adjusted change-from-baseline J-T peakC 
Kel elimination rate 
Kg kilogram MedDRA Medical Dictionary for Regulatory Activities 
Mg milligram 
NONMEM nonlinear mixed effects modeling 
NSAID nonsteroidal anti-inflammatory drug 
N
2 nitrogen 
OTC over-the-counter 
O2 Oxygen 
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
 pCO 2 partial pressure carbon dioxide 
PD pharmacodynamic 
PETCO 2 end-tidal partial pressure carbon dioxide 
PK pharmacokinetic 
pO 2 partial pressure oxygen 
QA quality assurance 
QD once daily QTc heart rate-corrected QT interval 
ǻ47F  change-from-baseline in QTc 
ǻǻ47F  placebo-adjusted change-from-baseline QTc 
QTcF heart rate-corrected QT interval using the Fridericia 
correction 
RCF relative centrifugal force 
SAE serious adverse event SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
SAP statistical analysis plan 
SD standard deviation 
SOP standard operating procedure 
SpO
2 oxygen saturation 
t1/2 terminal half-life 
TEAE treatment-emergent adverse event 
Tmax time of C max 
VE55 minute ventilation at 55 mmHg partial pressure carbon 
dioxide 
 
 
  
U.S. FOOD AND DRUG ADMINISTRATION  
CDER / Office of Translational Sciences / Office of Clinical 
Pharmacology / Division Applied Regulatory Science  Protocol Number: SCR-012 
(Version 1.1) 
 
 Appendix C – Protocol Revision History 
PROTOCOL REVISION HISTORY 
 
 
 
  
 
  
 
   Protocol 
Number Version Effective Date Summary of Changes 
SCR-012 1 21 June 2022 Devel oped initial protocol  
SCR-012 1.1 21 July 2022 Updated protocol to reflect revised 
endpoints, assessments, and analyses 
method.  
Certificate Of Completion
Envelope Id: 2B6DD0381EEF404EABE8B630AC2A9B25 Status: Completed
Subject: Please DocuSign: SCR-012 Opioids DDI 2 Protocol_v1.1_21Jul2022_formatting.pdfSource Envelope: Document Pages: 79 Signatures: 2 Envelope Originator: Certificate Pages: 5 Initials: 0 Karrielynn GerlachAutoNav: EnabledEnvelopeId Stamping: DisabledTime Zone: (UTC-08:00) Pacific Time (US & Canada)Karrielynn.Gerlach@spauldingclinical.com
IP Address: 64.250.100.247 
Record Tracking
Status: Original             7/25/2022 2:28:35 PMHolder: Karrielynn Gerlach
             Karrielynn.Gerlach@spauldingclinical.comLocation: DocuSign
Signer Events Signature Timestamp
David Strauss
david.strauss@fda.hhs.govSponsor Study LeadSecurity Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
C37632FD-56B7-47FC-9B70-FAEE64302722
Using IP Address: 150.148.14.135
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 7/25/2022 2:37:47 PM
Viewed: 7/27/2022 11:02:14 AM Signed: 7/27/2022 11:02:39 AM
Electronic Record and Signature Disclosure: 
      Accepted: 10/25/2021 11:15:54 AM
      ID: 51a3664d-cfbd-4295-b370-e0bb8628e897
Jan Matousek
jan.matousek@spauldingclinical.comPrinicipal  InvestigatorSecurity Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 4E887FB2-4D29-4750-80F9-DF0904DAE3DCUsing IP Address: 12.11.209.41
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):    I have reviewed this documentSent: 7/27/2022 11:02:45 AM
Viewed: 7/27/2022 11:05:32 AM Signed: 7/27/2022 11:05:52 AM
Electronic Record and Signature Disclosure: 
      Accepted: 7/27/2022 11:05:32 AM
      ID: 4416af51-d41f-4877-9ce1-b565ff105094
In Person Signer Events Signature Timestamp
Editor Delivery Events Status Timestamp
Agent Delivery Events Status Timestamp
Intermediary Delivery Events Status Timestamp
Certified Delivery Events Status Timestamp
Carbon Copy Events Status Timestamp
Jennifer Boganschneider
jennifer.bogenschneider@spauldingclinical.comSecurity Level: Email, Account Authentication 
(Required)
Sent: 7/27/2022 11:02:45 AM
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
Witness Events Signature Timestamp
Notary Events Signature Timestamp
Envelope Summary Events Status Timestamps
Envelope Sent Hashed/Encrypted 7/25/2022 2:37:47 PM
Certified Delivered Security Checked 7/27/2022 11:05:32 AMSigning Complete Security Checked 7/27/2022 11:05:52 AMCompleted Security Checked 7/27/2022 11:05:52 AM
Payment Events Status Timestamps
Electronic Record and Signature Disclosure
ELECTRONIC RECORD AND SIGNATURE DISCLOSURE   
From time to time, Spaulding Clinical (we, us or Company) may be required by law to provide to 
you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully  and thoroughly, and if you can access this 
information electronically to your satisfaction and agree to this Electronic Record and Signature 
Disclosure (ERSD), please confirm y our agreement by selecting the check- box next to ‘I agree to 
use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign 
system. 
 
Getting paper copies   
At any time, you may request from us a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may acce ss the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents fr om our office to you, you will be charged a 
$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below. 
 
Withdrawing your consent   
If you decide to receive notices and disclosure s from us electronically, you may at any time 
change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below. 
 
Consequences of changing your mind   
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in tr ansactions with you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us. 
 
All notices and disclosures will be sent to you electronically     !
!  
	
  
" ! !
Unless you tell us otherwise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documen ts that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same meth od and to the same address that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the pa ragraph immediately above  that describes the 
consequences of your electing not to receive delivery of the notices and disclosures electronically from us. 
 
How to contact Spaulding Clinical:   
You may contact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information fr om us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows: To contact us by email send messages to: jeffrey.sanchez@spauldingclinical.com 
 
To advise Spaulding Clinical of your new email address   
To let us know of a change in your email address where we should send notices and disclosures 
electronically to you, you must send an email message to us 
at jeffrey.sanchez@spauldingclinical.com and in the body of such request you must state: your 
previous email address, your new email address.  We do not require any other information from 
you to change your email address.  
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Spaulding Clinical   
To request delivery from us of paper copies of  the notices and disclosures previously provided 
by us to you electronically, you must send us an email 
to jeffrey.sanchez@spauldingclinical.com and in the body of such request you must state your 
email address, full name, mailing addr ess, and telephone number. We will bill you for any fees at 
that time, if any. 
 
To withdraw your consent with Spaulding Clinical   
To inform us that you no longer wish to receive future notices and disclosures in electronic 
format you may: 
i. decline to sign a document from within your signing session, and on the subsequent page, 
select the check-box indicating you wish to withdraw your consent, or you may; 
ii. send us an email to jeffrey.sanchez@spauldingc linical.com and in the body of such request 
you must state your email, full name, mailing address, and telephone number. We do not need 
any other information from you to withdraw consent..  The consequences of your withdrawing consent for online documents will be that tran sactions may take a longer time to process.. 
 
Required hardware and software   
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer-guide-
signing-system-requirements .  
 
Acknowledging your access and consent to receive and sign documents electronically   
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we wi ll provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to prin t on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check- box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system.  
By selecting the check- box next to ‘I agree to use electronic records and signatures’, you confirm 
that: 
x You can access and read this Electronic Record and Signature Disclosure; and 
x You can print on paper this Electronic Record and Signature Disclosure, or save or send 
this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and 
x Until or unless you notify Spaulding Clinical as  described above, you consent to receive 
exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that  are required to be provided or made 
available to you by Spaulding Clinical during the course of your relationship with 
Spaulding Clinical. 